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CHAPTER 1  
General Introduction 
 
Invasive streptococcal pathogens are a global health concern.  Streptococcal pathogens 
continue to pose significant challenges for the treatment and prevention of invasive disease worldwide 
(96, 218, 228, 258).  The emergence of antibiotic resistance among streptococcal isolates adds to the 
relevance of this problem (151, 252).  Those at highest risk for invasive streptococcal disease include 
young children, the elderly and the immunocompromised (228).  The major human streptococcal 
pathogens associated with severe morbidity and mortality include Streptococcus pyogenes, 
Streptococcus agalactiae, and Streptococcus pneumoniae.  These species are often asymptomatically 
carried on the nasal, oral or vaginal mucosal surfaces, and can easily be transmitted to others.  For 
example, vaginal colonization of S. agalactiae is a precondition for in utero transmission to newborns 
(49).   
Infections of S. pyogenes (group A streptococcus, GAS) can manifest as acute symptoms 
including pharyngitis, cellulitis and pyoderma to more invasive diseases such as necrotizing fasciitis, 
sepsis, pneumonia and streptococcal toxic shock syndrome (188).  Additionally non-suppurative 
sequelae such as acute rheumatic fever and glomerulonephritis can complicate recovery efforts even 
after the infection has been resolved (69).  The recent resurgence of invasive GAS infections has 
impacted many populations of the world (50), and placed huge economic burdens in both developing 
and developed counties, with cost estimates up to $500 million per year in the United States alone 
(227).   
Streptococcus agalactiae (group B streptococcus, GBS) is a significant cause of morbidity and 
mortality in both newborns, the elderly and immunocompromised  (25, 293).  Neonatal GBS disease 
can manifest as either early onset with symptoms including respiratory failure and pneumonia 
progressing into bacteremia and septic shock, or late onset which is characterized as a bloodstream 
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infection with high risk of meningitis (207).  While advancements in diagnosis and prophylactic 
treatment have reduced early-onset neonatal mortality (78), the persistence of S. agalactiae-related still 
births, prematurity and late-onset disease remains a significant problem (107, 255).  Additionally, an 
increased incidence of skin infections, pneumonia and bacteremia among the elderly and 
immunocompromised (83, 97), along with an emerging resistance to penicillin, clindamycin and 
erythromycin among individual isolates is cause for concern (123, 150, 263). 
Streptococcus pneumoniae is a major cause of otitis media in children, as well as invasive 
diseases including pneumonia with bacteremia and/or empyema, and meningitis in newborns and the 
elderly.  The World Health Organization estimates that 1 million children die of invasive 
pneumococcal disease every year, mostly in developing countries (309).  Moreover, pneumococcal 
infections are the leading cause of death from a vaccine-preventable illness in children < 5 years of age 
(52).  As with the other streptococcal pathogens, a huge economic burden is associated with S. 
pneumoniae infection despite current vaccination efforts (280).  A licensed 23-valent pneumococcal 
polysaccharide vaccine has been in use since the late 1970s for the prevention of adult pneumococcal 
bacteremia (59); however, the burden of adult nonbacteremic pneumococcal pneumonia remains a 
significant challenge. 
Because the adult polysaccharide vaccine is not effective in children < 3 years of age, conjugate 
vaccines were developed for use in newborn vaccinations. The first licensed multi-valent 
pneumococcal vaccine for newborns (PCV7) was composed of polysaccharides from 7 different S. 
pneumoniae serotypes conjugated to the diphtheria toxoid.  PCV7 vaccination programs were initially 
extremely successful with not only significant reductions in invasive pneumococcal disease, but also a 
decreased frequency of antimicrobial resistant pneumococci (133).  The selective pressure imparted by 
PCV7 vaccination resulted in the emergence of new clinically relevant serotypes including the severe 
multi-drug resistant serotype 19A (70, 128), such that by 2010 the Centers for Disease Control and 
Prevention reported that 63% of invasive pneumococcal disease in children < 5 years of age was due to 
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non-PCV7 protected serotypes (53).  The vaccine was recently reformulated and licensed for 
protection against 13 clinically relevant serotypes (1, 3, 4, 6A/B/C, 7F, 9V, 14, 18C, 19A/F and 23F) 
(1-2); however, there are 96 documented pneumococcal serotypes with varying capsular 
polysaccharide structures categorized into 46 different serogroups based on immunological cross-
reactivity (118, 261).  Thus the possibility for new and emerging variants still exists. 
Although there are no licensed vaccines for either S. agalactiae or S. pyogenes, significant 
developmental efforts have been undertaken.  Five GBS serotypes (Ia, Ib, II, III, V) account for 96% of 
neonatal cases and 88% of invasive GBS disease in adults (229, 315).  Vaccines for all the 5 major 
capsular polysaccharide serotypes conjugated to tetanus toxoid have been constructed and show 
enhanced immunogenicity in early clinical trials (11-15, 220); however, the emergence of new 
serotypes is also a concern as observed with S. pneumoniae.  Additional surface molecules such as the 
Sip protein and immunogenic proteins from the GBS pilus are being investigated for their effectiveness 
as alternative vaccine targets to the capsular polysaccharide (38, 137, 193).  
The lack of a clear strategy for primary protection against S. pyogenes infection strengthens the 
need for an effective GAS vaccine (270).  The most advanced vaccine in development is both 
multivalent and type specific, made of short tandem peptides from the N-terminal region of the major 
surface M-protein (130).  The S. pyogenes M protein has long been investigated for GAS vaccine 
design; however, early observations related to the cross-reactivity of protective antibodies with human 
tissues such as heart (72)  brain (40), kidney or joint cartilage (10) led to initial concerns about 
vaccination safety, though many of these concerns have been addressed in current formulations.  
Additional pitfalls of this current vaccine relate to the high antigentic variability of the M protein (99, 
138).  Epidemiological studies of endemic populations with high GAS disease prevalence show 
extensive variability in M serotypes (146, 239).  One study in particular identified 31 different GAS M 
serotypes within a small Australian Aboriginal community over a 2 year period, with up to 11 different 
serotypes occurring at any given time (27).  Such variability could hinder the vaccine efficacy, 
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especially in countries with high endemic GAS disease (270).  Other vaccines currently in 
development target the conserved C-repeat region of the M protein (35-36, 238), the conserved GAS 
carbohydrate (129), C5a peptidase (136), streptococcal fibronectin-binding protein 1 (Sfb1) (292) and 
streptolysin S (73), though most are far from clinical trials.  
As outlined above, invasive streptococcal pathogens present a significant public health concern.  
Problems with treatment and prevention of invasive human streptococcal pathogens emphasize the 
importance of understanding both mechanisms of streptococcal pathogenesis and surface adaptations 
for the design of efficient vaccines and treatment options.  The use of model streptococcal pathogens 
such as Streptococcus iniae to address these issues may prove invaluable for the identification of novel 
vaccine targets and development of effective therapeutics.  The use of S. iniae to investigate the 
challenges that exist for infection control of streptococcal pathogens is discussed in greater detail in the 
following sections.   
Streptococcus iniae is an invasive systemic pathogen and model pathogen.  Streptococcus 
iniae is a -hemolytic, Lancefield serogroup negative, Gram positive streptococci originally isolated 
from the subcutaneous abscess of an Amazon freshwater dolphin (Inia geoffrensis) suffering from 
acute “golf ball disease” (231-232).  Aquatic species infected with S. iniae typically suffer from severe 
skin lesions, septicemia and meningoencephalitis (9).  Disease epidemics are often associated with 
seasonal increases in water temperature or poor water quality (22, 39, 144).  Streptococcocis of fish 
was not widely observed prior to the 1970s (247); however, the increased use of aquaculture for 
maintaining fish populations has resulted in the pandemic spread of S. iniae, with documented 
outbreaks affecting approximately 30 different aquatic species and losses totaling $100 million 
annually (4).   
The enormity of loss associated with S. iniae outbreaks prompted the development of a 
formalin-killed vaccine (90), and its successful implementation in large farming operations provided 
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significant relief for trout fisheries within Israel (22).  This success was short-lived when within 2 
years the emergence of an unprotected strain with altered serotype specificity resulted in massive 
outbreaks in previously vaccinated fish populations (7, 19, 165).  Reformulation of the vaccine was 
again followed by the emergence of a new variant that produced copious amounts of extracellular 
polysaccharides (EPS) (94).  The new EPS producing strains were hyperinflammatory and displayed 
an increase in disease severity and mortality (93).  Thus development of a reliable vaccine for S. iniae 
has been challenging and will require a better understanding of streptococcal surface variability (4).  
The emergence of unprotected strains of S. iniae following large scale vaccination equates to the 
problems observed with human vaccination against S. pneumoniae (128).  Testing the efficacy of novel 
streptococcal vaccine targets using S. iniae could be an efficient way to determine their long term 
effectiveness in large populations under strong selective pressure, minimizing the emergence of 
unprotected variant strains.  Such targets could then be further validated for their effectiveness against 
human streptococcal pathogens.  Novel targets for S. iniae vaccine development that are currently 
being investigated  include a putative iron binding protein Sip11 (58), hydrophobic membrane protein 
MtsB (320) and a DNA based vaccine expressing a secretory antigen Sia10 under the control of a 
cytomegalovirus immediate-early promoter (278).   
The specific identification of S. iniae among fish populations for epidemiologic monitoring has 
been difficult due to its similarity to several other streptococcal species including Streptococcus 
parauberis and Streptococcus difficilis. Thus even PCR based diagnosis toward various targets 
including the 16S rRNA gene, chaperonin HSP60 or the 16S-23S rRNA intergenic region has been 
problematic (26, 109, 319).  A breakthrough occurred when a S. iniae gene encoding a lactate oxidase 
(lctO) was identified, and found to be limited to a few streptococcal species such as S. equi and S. 
pyogenes (108).  Novel primer sets were designed (LOX1/LOX2)  which allowed for the specific 
identification of S. iniae through PCR amplification of lctO (194), providing a tool for determining the 
presence of S. inaie in large aquiculture systems.  During random screening of a fish farm in Northern 
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Australia, a novel lctO variant was identified that produced a larger, more efficient version of the 
enzyme, which may provide a competitive advantage against other S. iniae strains (212).  Examples 
such as this highlight the selective pressures placed on emerging pathogenic strains in aquaculture, and 
underscore the importance of developing efficient identification and control strategies. 
Documented cases of zoonitic S. iniae infection began in the mid 1990s when in the span of a 
year 4 patients developed bacteremic cellulitis from injuries obtained while handling fresh fish (304).  
Since then sporadic cases have been documented worldwide, all occurring after injury from infected 
fish (95, 171, 277, 305).  Human clinical isolates of S. iniae show increased virulence in animal 
infection models compared to commensal fish strains (101).  Furthermore, recent human isolates 
display enhanced survival and replication over earlier isolates when cultured in whole blood (95).  
Nonetheless, S. inaie is not considered an emerging pathogen of human concern (95, 260).   
S. iniae has been used as a model pathogen for the study of systemic streptococcal infection in 
several native hosts including hybrid striped bass (42, 44), rainbow trout (18, 41, 88), barramundi (8), 
tilapia (88, 320) and zebrafish (202-203, 214).  Numerous virulence factors have been described that 
severely influence the morbidity and mortality caused by this pathogen.  Many of these factors are also 
critical for virulence of human streptococcal pathogens as well, providing relevance for the use of S. 
iniae as a model pathogen for the study of invasive streptococcal infection.   
In concordance with many invasive pathogens, the majority of virulence factors described for 
S. iniae protect against opsonophagocytic killing by neutrophils (81, 110, 196, 306).  S. iniae contains 
a homolog of the major streptococcal M protein, which can bind fibrinogen as well as the FC region of 
immunoglobulin to inhibit opsonization (8, 18).  S. iniae also produces a C5a peptidase to hydrolyze 
the neutrophil chemoattractant complement factor C5a (180); however, unlike the S. pyogenes 
homolog, the S. iniae protein is not observed in cultured supernatants, and mutants show no attenuation 
in vivo suggesting a minor pathogenic role.  The streptolysin S cytolysin (SLS) of S. inaie is 
homologous to that of S. pyogenes and contains hemolytic activity against erythrocytes, lymphocytes 
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and neutrophils (102).  Furthermore, expression of the S. iniae homolog in an S. pyogenes SLS mutant 
restored hemolytic activity (181).  Expression of the SLS locus appears to be controlled by the SivSR 
two-component signal transduction system (TCS) (31).  SivSR also regulates the cfi-encoded pore-
forming toxin CAMP factor (31), and has been shown in influence capsule production as well (30).   
S. iniae produces a complex polysaccharide capsule that facilitates protection from 
opsonophagocytic killing.  The genes required for capsule biosynthesis are encoded in an operon of 
approximately 21 kbp in size (185) that is transcriptionally controlled by the conserved CpsA 
regulator, a member of the LytR_cpsA_psr family (117).  Deletion of cpsA results in reduced capsule 
biosynthesis and severe attenuation in vivo (185).  The capsule operon was initially characterized 
following transposon mutagenesis studies performed on two separate strains of S. iniae: strain 9117, 
isolated from a human patient with bacteremic cellulitis (305), and strain NUF631, isolated from a 
diseased Japanese flounder (Paralichtys olivaceus) (262).  Both studies reported that transposon 
insertions affecting capsule production occurred within the same sets of genes: cpsH, orf276 and cpsM, 
with one additional mutant in cpsK for 9117, suggesting either the importance of these genes in 
capsule production or the amenability of these regions for transposon insertion.  All capsule mutants 
from strain NUF631 were shown to have decreased capsule production accompanied with decreased 
survival in whole blood and macrophages (262).  Mutants in either orf276 or cpsH of strain 9117 
displayed a similar reduction in capsule production and increased susceptibility to killing in whole 
blood (185, 202).  In contrast, the cpsM mutant of strain 9117 displayed a significant increase in 
capsule production with an accompanying increased survival in whole blood (185).  Additionally, none 
of the 9117 capsule mutants were found to be susceptible to macrophage-dependent killing (202).  The 
difference in macrophage susceptibility between 9117 and NUF631 is most likely due to strain 
differences, as human isolates tend to be more virulent than those from fish (101); however the reason 
for the inverse phenotypes related to mutations in cpsM is still unclear.  CpsD has also been studied for 
its role in capsule production, and mutants display similar phenotypes to those of cpsH, including 
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reduced capsule production, sensitivity to cationic antimicrobial peptides and an increased 
susceptibility to killing in whole blood (182). 
S. inaie is a strong candidate for use as a model pathogen to study invasive streptococcal 
disease.  The prevention challenges, disease invasiveness and myriad of virulence determinants are 
homologous to those observed with human streptococcal pathogens.  The knowledge gained from 
utilizing S. iniae as a model pathogen could enable direct comparison for use in control of human 
streptococcal pathogens.  Moreover, the use of a natural host such as the zebrafish to investigate 
disease pathogenesis and infection control could be a powerful and cost-effective tool when fishing for 
the ultimate therapeutic strategy.  
Zebrafish as a biological model system.  The zebrafish (Danio rerio) is a tropical freshwater 
fish that has emerged as an important tool for biological studies.  Their small size, relative low cost and 
ease of breeding allows for studies to be performed in large scale.  Zebrafish have been used for 
studying diverse areas of biology including vertebrate development (46, 85, 219), aging (152), 
cardiovascular disease (54),  cancer (178, 223), neuroscience (141, 246) and toxicology (127, 176, 
213).  Zebrafish have also proven to be a powerful tool for investigations into immune system 
development, function and disease (197, 276).  The zebrafish immune system is closely related to that 
of humans, with both functional innate and adaptive arms (198, 208, 271, 276, 284-285).  Zebrafish do 
not have a fully functional adaptive immune system until around 4 to 6 weeks of development (167-
168), which offers a unique opportunity to study the functional role of innate immune components in 
the absence of adaptive immunity.  Moreover, with a complete sequenced genome, useful tools for 
forward and reverse genetic techniques, gene silencing as well as inducible transgenics,  new 
applications for this unique model organism are constantly emerging (6, 71).   
Several technologies for genetic manipulation of the zebrafish make it a useful system for 
disease investigation.  Gene silencing using morpholinos continues to be a valuable tool for 
investigating gene function.  Morpholinos are modified antisense oligos that are similar to DNA and 
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RNA oligonucleotides, except that they have a morpholine rather than a ribose ring and are thus 
extremely resistant to nucleases.  Morpholinos are micro-injected into embryos and decrease or silence 
expression of a specific target gene by either blocking translation initiation or inhibiting splicing (80, 
86, 210).  The generation of zebrafish mutants can be done by chemical mutagenesis using agents such 
as ethylnitrosourea (ENU).  Heterozygous germ line mutations for a specific phenotype can be mapped 
by Targeting Induced Local Lesions in Genomes (TILLING) (79, 273).  Additionally, retroviral  or 
transposon insertion libraries can be made by injecting retroviral constructs into blastula-staged 
embryos, generating chimeric embryos in which clones of cells within the embryo contain different 
insertions (5, 147).  Insertions in cells that ultimately form the germ line are transmitted to the next 
generation, and harvested sperm can be used to prepare genomic DNA for sequencing around the 
insertion.  Furthermore, technologies for using inducible transgenes have also been proven effective in 
zebrafish.  Tissue specific promoters can be used to drive expression of the reverse-Tet-controlled 
transactivator (rtTA).  In the presence of Doxycycline, the rtTA protein can then bind to a second 
rtTA-responsive element to drive expression of a gene of interest or  reporter gene, such as green 
fluorescent protein (131).  Alternatively the Cre/loxP system, which is traditionally used for the 
generation of conditional mutants, has been used in zebrafish for transgene induction.  In such a 
system, tissue specific promoters drive expression of the Cre-recombinase, whereby a loxP-flanked 
element within a promoter region is removed for reporter gene expression or expression of a gene of 
interest (221).  Additionally zebrafish larvae remain translucent for several weeks.  Taking advantage 
of this trait, zebrafish strains have been created in which macrophages and neutrophils express green 
fluorescent protein, thus allowing for real-time imaging of the behavior of these cell types to various 
stimuli in vivo (177).   The ability to easily manipulate either the pathogen or the host for the study of 
infectious disease, as well as real time imaging of disease progression could allow for unprecedented 
insight into the host-pathogen interactions that occur during invasive infectious disease.   
   
      10
The zebrafish has been a useful tool for the identification of streptococcal virulence genes 
through large-scale mutagenesis of streptococcal pathogens.  In separate signature-tagged mutagenesis 
(STM) studies performed on S. iniae and S. pyogenes, 12 individually tagged STM vectors were used 
to generate separate libraries from which individual mutants were pooled and injected into zebrafish 
(153, 202).  At specific time points tissues were removed and screened by PCR for the 
presence/absence of the specific mutants based on the individual STM tag.  Mutations in genes 
required for survival in the host were identified by the presence of the mutant in broth culture, but not 
in tissue homogenates.  This successful technique identified several novel streptococcal virulence 
factors, and highlighted the importance of several previously characterized systems.  
Zebrafish have also been used to investigate complex host/pathogen interactions involving 
macrophage recruitment, granuloma formation and spread of Mycobacterium marinum.  The ESX/RD1 
secretion system locus of M. marinum was found to be involved in granuloma formation (296) through 
the active recruitment of host macrophages to the expanding granuloma (75).  The 6 kDa early secreted 
antigen target (ESAT6) secreted by the RD1 locus was determined to induce production of matrix-
metalloproteinase 9 (MMP9) in neighboring epithelial cells.  The induction of MMP9 is what triggers 
macrophage recruitment and granuloma expansion, which is critical for mycobacterial spread (297).  
Virulence properties of several other pathogens have been studied using zebrafish infection models 
including bacterial pathogens such as Salmonella typimurium (274),  Pseudomonas aeruginosa (62, 
230), Francisella sp. (295) and Edwardsiella tarda (236), as well as viral pathogens such as the 
Infectious Spleen and Kidney Necrosis Virus (310) and Herpes Simplex Virus 1 (132).   
Polymorphonuclear granulocytes.  Neutrophils, or polymorphonuclear leukocytes, are 
extremely important for protection against microbial pathogens.  Neutrophils are professional 
phagocytic cells which eliminate microbes through a variety of bactericidal mechanisms (256).  
Patients with congenital neutropenia or chronic granulomatous disease, or who display increased 
neutrophil destruction due to chemotherapy are at an increased risk for severe fungal and bacterial 
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infections (191).  Neutrophils are produced from myeloid precursors in the bone marrow in large 
number and circulate in the blood stream at concentrations ranging from 3 to 6 million cells per ml in 
healthy individuals (175).  They are easily identified after Giemsa staining by their characteristic 
multi-lobed nucleus and large concentration of cytoplasmic granules.  The neutrophil granules contain 
clusters of antimicrobial and cytotoxic substances that are delivered to the phagosome or to the exterior 
of the cell during degranulation. 
If microorganisms circumvent the physical barriers of the skin or mucous membranes, 
neutrophils are rapidly recruited to the site of infection by responding to chemotatic signals produced 
by neighboring cells and vascular endothelium nearest the infection site (243).  Neutrophils escape 
circulation through a series of sequential events that begin with initial weak “slow rolling” interactions 
of selectins on both the neutrophil and activated vascular endothelial surfaces (308).  This is followed 
by firm adhesion to the endothelial surface through interactions involving neutrophil 2-integrins and 
the endothelial immunoglobulin superfamily members Inter-cellular Adhesion Molecule (ICAM) -1 
and ICAM-2.  Strong adhesion triggers morphological changes for the neutrophil in preparation for 
diapedesis.  A collection of endothelial adhesion molecules including ICAM-1 and -2, Junctional 
Adhesion Molecules (JAM), Endothelial cell Selective Adhesion Molecule (ESAM), and several 
cadherins interact with similar molecules on the neutrophil cell surface to both assist in neutrophil 
paracellular migration as well as stabilization of the endothelial cell junction.  Neutrophils traverse the 
basal membrane and tissues by breaking down the connective tissue with several enzymes including 
elastases and matrix metallo proteinases (308). 
Neutrophils in tissue display an increased phagocytic capacity compared to when in circulation 
(267).  They also produce various chemokines for recruitment of additional inflammatory cells.  
Neutrophils phagocytose and kill microbes through a complex series of events which begin with the 
pathogen being engulfed into a early phagosomal vacuole (172).  Pathogens within the nascent 
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phagosome are exposed to a burst of reactive oxygen species following assembly of the NADPH 
oxidase. This is followed by a series of maturation events which involve a reduction of phagosomal 
size and successive fusion of the pre-formed gelatinase, specific, and azurophilic granules (172, 256).  
These granules deliver a diverse arsenal of bactericidal compounds including various antimicrobial 
peptides, proteases and lysozyme in an attempt to eliminate the pathogen (98). 
Neutrophils are also able to undergo a very specific type of programmed cell death (netosis) 
that requires components of autophagy and the generation of superoxide, leading to the release of a 
DNA/histone containing net-like extracellular trap (244).  These neutrophil extracellular traps (NETs) 
are able to contain invading pathogens in a mesh-like network to limit bacterial spread (37).  Mass 
spectrometry analysis of NETs reveals the association of 24 different cationic bactericidal proteins 
within the NETs (288).  NETs have been demonstrated to play a significant role in protection against 
several pathogens including Leishmania amazonensis (112), Candida albicans  (288),  Aspergilis 
fumigates (195) and Haemophilus influenzae (140).  Several pathogens including S. pyogenes (56), S. 
pneumoniae (204) and Staphylococcus aureus (23) have been shown to produce extracellular DNases 
thought to dissolve NETs and promote bacterial spread. 
 Methionine and single carbon metabolism.  The transfer of single carbon groups (i.e. methyl/ 
formyl groups) is an important chemical modification for compounds involved in a myriad of cellular 
processes.  These single carbon (C1) units are carried throughout the cell by tetrahydrofolate (THF), a 
reduced form of folic acid.  C1-THF derivatives are involved in single-carbon transfer reactions for the 
synthesis of purines, formylmethionyl-tRNA, thymidylate, pantothenate, glycine, serine and 
methionine (76, 190).  Sulfonamides are antibacterial compounds that target the enzyme dihydrofolate 
reductase (DHFR) involved in the synthesis of THF,  and are thus effective broad-spectrum 
antimicrobials due to the variety of downstream pathways affected by THF deficiency (119). 
THF primarily accepts methyl groups from serine, by the action of the serine 
hydroxymethyltransferase (GlyA), or glycine, by the glycine cleavage complex (GCV), to form 5,10-
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methyleneTHF, which is the central compound in C1 metabolism (Fig. 1).  5,10-methyleneTHF can 
either donate a C1 group directly for synthesis of thymidine nucleotides, be oxidized by NADP+ to 
form 5,10-methenylTHF involved in purine nucleotide biosynthesis, or can be reduced by NADPH to 
5-methylTHF for the biosynthesis of methionine (76).  
Biosynthesis of methionine involves metabolic pathways for de novo biosynthesis of cysteine, 
which is then converted to homocysteine through a cystathionine intermediate.  The methyl group of 5-
methylTHF is transferred to homocysteine to form methionine by the action of either the cobalamin-
independent methionine synthase (MetE) (82), or cobalamin-dependent methionine synthase (MetH) 
and Vitamin B12 (16) (Fig. 1).  Methionine is not only an important amino acid in translation and 
protein synthesis, but is also the precursor for the synthesis of S-adenosylmethionine (SAM).  SAM is 
produced from methionine and adenosine-triphosphate (ATP) by the action of S-adenosylmethionine 
synthase (MetK).  SAM is the primary methyl donor for transmethylation and transsulfuration 
reactions, as well as polyamine synthesis (186).  S-adenosylhomocysteine is formed as a reaction 
product, and is rapidly converted back to homocysteine to be reused in the synthesis of methionine, 
thus completing the methyl cycle. 
Regulation of methionine biosynthesis has been best characterized in Gram negative organisms. 
MetJ is a transcriptional repressor that binds excess SAM as a cofactor to repress transcription of the 
de novo methionine biosynthesis genes when methionine levels are sufficient (Fig. 1) (169).  This 
transcriptional repression is relieved under sulfur limiting conditions when SAM levels drop and 
methionine biosynthesis is required for synthesis of SAM (113).  Additionally, a LysR family 
transcriptional regulator, MetR, utilizes homocysteine as a cofactor to compete with the MetJ:SAM 
complex and increase methionine biosynthesis through transcriptional activation of metE and metF due 
to a buildup of homocysteine (Fig. 1) (47, 65, 183, 234, 290-291).  MetR also activates expression of 
the GlyA serine hydroxymethyltransferase to increase synthesis of 5,10-methyleneTHF for 
downstream use in methionie biosynthesis (234). 
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Figure 1.  Schematic of metabolic pathways associated with single-carbon (C1) unit flow. This 
diagram represents possible outcomes for the C1-tetrahydrofolate (THF) derivatives, and how C1-THF 
derivatives are used for biosynthesis of methionine and ultimately S-adenosylmethionine (SAM).  
Only genes involved in metabolic processes discussed in the text are shown italicized in black.  (SAM) 
and (HC) indicate the transcriptional regulators MetJ and MetR utilize S-adenosylmethionine and 
homocysteine as cofactors respectively.  Solid arrows indicate enzymatic reactions, dashed arrows 
represent transcriptional activation, and the dashed line indicates transcriptional repression. 
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Apoptosis.  Apoptosis is a natural pathway of programmed cell death that is utilized for 
maintaining homeostasis, as part of the developmental process of multicellular organisms, and by the 
immune system for removal of damaged or infected cells (316).  Apoptosis can also be triggered under 
conditions of cell stress such as DNA damage or increased generation of reactive oxygen species 
(ROS).  Activation of regulatory cascades leading to apoptosis occurs through both intrinsic and 
extrinsic pathways in the cell.  In the intrinsic pathway, various stimuli occurring from cell stress can 
disturb the balance of Bcl-2 family proteins, which alter the mitochondrial transmembrane potential 
leading to the release of cytochrome c into the cytosol (163).  Cytochrome c in the cytosol initiates 
activation of the apoptosome, which in turn triggers a signaling cascade resulting in the activation of 
the cysteine-dependent aspartate-directed protease 3 (caspase 3).  Caspase 3 is the terminal caspase of 
the pro-apoptotic pathways and upon activation cleaves various targets to promote apoptotic death 
(77).  In the extrinsic pathway, ligands such as Fas (FasL) or tumor necrosis factor alpha (TNF) bind 
to death receptors on the cell surface (253). Trimerization of bound receptors promotes recruitment of 
various adaptor proteins that ultimately leads to the activation of caspase-8/10, triggering a cascade of 
signaling events that leads to the activation of caspase 3 and subsequent apoptotic death .  Apoptosis 
must be tightly regulated to ensure that spontaneous activation of these catastrophic pathways does not 
occur.  Fas-induced apoptosis by the extrinsic pathway can be effectively blocked by proteins such as 
the Flice-Inhibitory Protein (FLIP), while apoptosis triggered from the intrinsic pathway is inhibited by 
stabilization of the mitochondrial membrane potential through Bcl-2 family proteins such as BclXL, or 
by the cytokine response modifier A (CrmA).  In addition, activation of caspase-3 by either pathway 
can be blocked by inhibitor of apoptosis proteins (IAPs) such as XIAP, which bind directly to caspase 
3 (122).  Moreover, the protein kinase Akt can be activated by various growth factors to promote cell 
survival through phosphorylation-inactivation of the pro-apoptotic protein Bad, along with activation 
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of IKKa that ultimately leads to NFkB activation and subsequent expression of pro-survival genes such 
as FLIP and BclXL (122).   
 Many bacterial pathogens have evolved different strategies to either induce or inhibit apoptosis 
to promote their own survival (303).  Pathogens such as Shigella, Salmonella, and Listeria have 
evolved strategies to induce apoptosis of phagocytic cells in order to escape phagolysosomal killing 
(105), while others such as Mycobacterium, Chlamydia, and Coxiella inhibit apoptosis using the 
intracellular environment as a protective niche (187, 303).  Bacterial pathogens that inhibit apoptosis 
do so by a variety of strategies.   E. coli K1 infection of murine macrophages results in expression of 
the pro-survival gene BclXL and blockage of cytochrome c release (275), whereas Shigella flexneri 
inhibits apoptosis in epithelial cells by directly blocking activation of caspase-3 (61). 
 S. agalactiae and S. pneumoniae-infected phagocytes have been shown to induce apoptosis by 
48 hours post infection (287).  In contrast, S. iniae (9117) has been shown to inhibit apoptosis in 
macrophages 24 hours post infection (184).  Furthermore, two different isolates of S. iniae (9033 and 
173) resulted in the inhibition of apoptosis in primary fish phagocytes (281).  The contrasting results 
between S. pneumoniae, S. agalactiae, and S. iniae may be due to differences in the time points 
investigated as well as the experimental conditions. Further studies are needed to determine the means 
by which streptococcal pathogens affect host apoptotic pathways.  Inhibition of the normal apoptotic 
pathways would allow for prolonged intracellular survival, which could facilitate dissemination and 
invasion into distant tissues. 
Discovery of CpsY as a S. iniae virulence determinant.  Initial studies into the transcriptional 
regulation of the capsule operon of S. iniae revealed the presence of a second transcriptional regulator, 
CpsY, which is inversely oriented upstream of cpsA and the capsule operon, separated by a shared 
promoter region (Fig. 2) (185).  CpsY was originally predicted to regulate capsule biosynthesis in S. 
agalactiae due to its adjacent location to the capsule operon (156).  Transcriptional reporter constructs 
using either the cpsY or cpsA promoters controlling expression of the alkaline phosphatase gene 
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revealed significantly reduced expression from both the cpsY and cpsA promoters in a mutant with an 
in-frame-deletion of the cpsY gene (cpsY), suggesting that CpsY transcriptionally activates both itself 
and the capsule operon (184).  However, quantification of capsule biosynthesis by percoll gradient 
centrifugation showed that the cpsY mutant had only slightly decreased levels of capsule compared to 
wild type (185), indicating that CpsY has minimal effect on capsule biosynthesis.  This was confirmed 
by quantitative PCR where no difference in expression of the capsule operon was observed in the 
cpsY mutant.  Alkaline phosphatase promoter-reporter constructs for non-CpsY regulated promoters 
were also found to have low expression in the cpsY mutant (personal observations), suggesting that 
the observed dichotomy between qPCR, percoll gradient centrifugation and promoter-reporter results 
may be due to the inherent inability of the cpsY mutant to effectively express the alkaline phosphatase 
reporter, perhaps related to an uncharacterized toxicity of the gene product toward the cpsY mutant.   
Infection of zebrafish by intramuscular injection of the cpsY mutant revealed a highly 
attenuated phenotype with minimal invasion to the brain and decreased systemic survival (185).  
Investigation into the regulation of cpsY showed that cpsY-promoter activity increased throughout 
logarithmic growth phase when cultured in Todd-Hewitt yeast broth (ThyB), but not when cultured in 
brain-heart infusion medium (BHI) (201).  Immunohistochemistry of infected zebrafish revealed that 
expression from the cpsY promoter was rapidly shut off upon injection into the muscle tissue and 
remained off for the first 60 minutes post infection (p.i.); however, expression in the muscle tissue was 
observed by 24 hours (201).  In contrast, expression from the cpsY promoter was observed as early as 
15 minutes p.i. in the heart and 30 minutes p.i. in the spleen (201).  Furthermore, at these early time 
points, expression appeared to occur only when the bacteria were localized intracellular in phagocytic 
cells.  Overall the data suggest that CpsY is tightly regulated and may play a role in intracellular 
survival in vivo. 
CpsY shares homology to the LysR family of transcriptional regulators (LTTR), which regulate 
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Figure 2. Capsule synthesis operon map of S. iniae (accession no. AY904444).  Bent arrows indicate 
transcriptional promoter regions.   
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the expression of genes with a wide array of functions (254).  CpsY is highly conserved among the 
streptococci, and homologs are found in both Gram positive and Gram negative species.  CpsY 
orthologs in Streptococcus mutans and S. agalactiae have been renamed MetR and MtaR respectively 
due to their role in methionine transport and metabolism (259, 268), but evidence suggests that MtaR 
has significant regulatory function unrelated to methionine metabolic processes as well (42). The 
regulatory role CpsY has on methionine metabolic processes, as well as streptococcal virulence is the 
major focus of this work and will be comprehensively discussed in the following chapters.   
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CHAPTER 2 
The Streptococcus iniae transcriptional regulator CpsY is required for protection 
from neutrophil-mediated killing and proper growth in vitro. 
 
Abstract 
The ability of a pathogen to metabolically adapt to the local environment for optimal 
expression of virulence determinants is a continued area of research.  Orthologs of the Streptococcus 
iniae LysR family regulator CpsY have been shown to regulate methionine biosynthesis and uptake 
pathways, but appear to influence expression of several virulence genes as well.  A S. iniae mutant 
with an in-frame deletion of cpsY (cpsY) is highly attenuated in a zebrafish infection model.  The 
cpsY mutant displays a methionine-independent growth defect in serum, which differs from the 
methionine-dependent defect observed for orthologous mutants of S. mutans and S. agalactiae.  On the 
contrary, the cpsY mutant can grow in excess of WT when supplemented with proteose peptone, 
suggesting an inability to properly regulate growth.  CpsY is critical for protection of S. iniae from 
clearance by neutrophils in whole blood, but is dispensable for intracellular survival in macrophages.  
Susceptibility of the cpsY mutant to killing in whole blood is not due to a growth defect because 
inhibition of neutrophil phagocytosis rescues the mutant to WT levels.  Thus CpsY appears to have a 
pleiotropic regulatory role for S. iniae, integrating metabolism and virulence. Furthermore S. iniae 
provides a unique model to investigate the paradigm of CpsY-dependent regulation during systemic 
streptococcal infection. 
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Introduction 
Our understanding of the diverse repertoire of transcriptional signaling networks that 
orchestrate optimal expression of virulence genes dependent upon the metabolic status of the cell is 
quickly expanding (265, 313).  Metabolic adaptations to the various environments encountered by a 
pathogen within a host prove to be tremendously complex and under studied (87).  Recent work on 
streptococcal pathogens has revealed components of these regulatory pathways that relate the 
nutritional status of the cell to control of growth phase and expression of virulence genes (3, 134, 145, 
148, 192, 209, 272). 
S. iniae is a major aquatic pathogen (88-89) that causes an invasive systemic infection with 
severe bacteremia culminating in meningoencephalitis (4).  Many instances of zoonoses have been 
reported as a result of handling infected fish, typically resulting in a bacteremic cellulitis (95, 170, 
305).  The severity of an S. iniae infection is due in part to the ability to rapidly disseminate from the 
site of infection through the blood stream and invade systemic tissues (185).  The complex 
pathogenicity of S. iniae, and other systemic streptococcal pathogens, is reflected in the diversity of 
genes that are critical to a successful infection (9, 142, 300).  Several classical streptococcal virulence 
factors have been shown to be important for the virulence of S. iniae, including the SivS/R-regulated 
streptolysin S and CAMP factor (31, 181), as well as the major surface M protein (180).  S. iniae also 
contains a polysaccharide capsule that functions for protection from phagocytic clearance in whole 
blood (182, 185, 202).  Furthermore, several genes not previously studied for their virulence traits have 
been shown to have critical roles during S. iniae infection of hybrid striped bass (HSB), including 
phosphoglucomutase (pgmA) (45) and a novel polysaccharide deacetylase (pdi) (200). 
We previously established the importance of a highly conserved LysR family transcriptional 
regulator, CpsY, in a zebrafish infection model (185).  Deletion of cpsY (cpsY) increased zebrafish 
survival by 40% 4 days post-infection.  Moreover, the cpsY mutant displayed a unique inability to 
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disseminate to the brain within the first hour post-infection.  CpsY was originally predicted to regulate 
capsule biosynthesis in Streptococcus agalactiae due to its adjacent location to the capsule operon 
(156).  Further research determined that CpsY has little effect on capsule production in both S. 
agalactiae (259) and S. iniae (185).  Rather, CpsY was renamed MtaR in S. agalactiae (259) and MetR 
in S. mutans (268) because of its influence on methionine biosynthesis and uptake.  However, the 
regulatory function of MtaR in S. agalactiae appears to extend beyond methionine metabolism (42).  
In the present study, we define a critical role for CpsY during S. iniae systemic infection.  We 
show that CpsY is required for intracellular survival in neutrophils, but not macrophages, and that this 
is critical for bacterial survival in whole blood.  Furthermore, we discuss variations in the CpsY-
dependent regulation of methionine supply pathways that exist among streptococcal pathogens. 
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Materials and Methods 
Bacterial strains, media and culture conditions.  Streptococcus iniae 9117 is a human 
clinical blood isolate from a patient with cellulitis (101).  A mutant containing an in-frame deletion of 
the cpsY gene used in this work was constructed previously (185).  Streptococcal strains were routinely 
cultured in Todd-Hewitt broth (BBL) supplemented with 0.2% yeast extract (BBL) (THY) in conical 
tubes without shaking at 37 oC.  For bacterial enumeration, serial dilutions were plated on THY agar 
plates and incubated at 37 oC in 5% CO2.  In all assays, overnight bacterial cultures were diluted 1:50 
in fresh medium, and grown to mid-exponential phase (OD600 0.225) unless otherwise stated. 
Bacterial growth curves.  Overnight bacterial cultures were diluted 1:50 in 96-well plates 
containing a 200 l total volume of THY or C medium (189), supplemented with either 400 g ml-1 L-
methionine (Sigma) or 2% proteose peptone #3 (BBL) when required.   The plates were incubated at 
37 oC in 5% CO2, and OD600 values were measured every 30 min using a VersamaxTM microplate 
reader (Molecular Devices). 
Growth assays in human serum were performed as previously described for Streptococcus 
agalactiae (259).  Briefly, non-heparinized blood was obtained from human volunteers by 
venipuncture, allowed to clot and centrifuged at 1000 x g for 5 min.  Mid-exponential phase cultures of 
S. iniae strains grown in THY were collected by centrifugation, washed 2 times in phosphate buffered 
saline (PBS, Invitrogen) and diluted to 1 x 105 CFU ml-1 in PBS.  Ten microliters of diluted bacteria 
was added to 1 ml of DMEM with 50% human serum in a 1.5 ml microcentrifuge tube, supplemented 
with 400 g ml-1 L-methionine (Sigma) when required.  Tubes were incubated at 37 oC with gentle 
rotation.  At the indicated time points, bacterial growth was determined by serial dilution on THY agar. 
Zebrafish infections.  Groups of 6 zebrafish (Danio rerio) adults were infected by 
intramuscular (i.m.) injection into the dorsal muscle with either S. iniae WT or the cpsY mutant from 
mid-exponential phase cultures as previously described (215).  A 30-gauge needle was used to inject 
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10 l of a 1 x 107 CFU ml-1 bacterial suspension in PBS for an infectious dose of 1 x 105 CFU.  
Zebrafish were euthanized with a lethal dose of Ethyl 3-aminobenzoate methanesulfonate (Tricaine, 
Sigma) at the indicated time point, and specific organs were harvested and gently homogenized in 300 
l PBS.  One hundred microliters of the homogenate was loaded into a cytology funnel (Thermo), 
centrifuged onto glass slides for 3 min at 700 rpm in a Cytospin 1 centrifuge (Shandon Elliott) and 
stained using the HEMA 3 stain set (Fisher Scientific).  Slides were viewed and documented with an 
Axioskop 40 microscope (Carl Zeiss, Inc.) fitted with an AxioCam MRc camera. 
RNA isolation and quantitative polymerase chain reaction (qPCR).  Bacteria were 
subcultured to logarithmic phase or early stationary phase in either THY or THY supplemented with 
2% proteose peptone #3 (TP).  When required, 4 mM L-methionine (Sigma) or homocysteine (Sigma) 
was added for 30 min upon reaching the appropriate growth phase.  Five milliliters of culture was 
centrifuged and resuspended in 1 ml phosphate buffered saline (PBS) with 25 mg ml-1 lysozyme 
(Sigma) and 50 U of mutanolysin (Sigma).  Following 30 min incubation at 37 oC, the bacteria were 
centrifuged, resuspended in 1 ml Trizol (Sigma) and incubated at room temperature for 5 min.  Two 
hundred microliters of chloroform was added to the suspensions, mixed vigorously and incubated an 
additional 3 min at room temperature.  The preparations were centrifuged 13,000 x g at 4 oC for 15 
min.  The aqueous phase was transferred to a fresh microcentrifuge tube, mixed with 500 l 
isopropanol and incubated 10 min at room temperature.  The samples were centrifuged 13,000 x g at 4 
oC for 15 min, washed twice with 70% ethanol, and resuspended in 100 l of water.  Contaminating 
DNA was digested with 5 g of DNaseI (Qiagen) at 37 oC for 2 hrs, and RNA was purified using the 
RNeasy® MinEluteTM cleanup kit (Qiagen).   For isolation of macrophage RNA, infected or mock-
treated cells were washed twice in PBS, and RNA was collected using the SV total RNA isolation kit 
(Promega) per manufacturer instructions. 
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For qPCR reactions 100 g of total RNA was combined in 20 l total reaction volumes with 
0.2 M forward and reverse primers, Express SYBR® GreenERTM (Invitrogen) and Express 
SuperScript® Mix (Invitrogen) per manufacturer instructions.  Primer sequences for transcriptional 
analysis of S. iniae were as follows: recA fwd 5’-CTCAGGTGCTGTTGATTTGG-3’, recA rev 5’-
TGCAGAGAGTTTACGCATGG-3’; atmB fwd 5’-CCCGTTGGGATAAAATTGAA-3’, atmB rev 5’-
CACCATTTGCAACTGCCTTA-3’.  Primer sequences for transcriptional analysis of infected 
macrophages were as follows:  -actin fwd 5’-TAAAACGCAGCTCAGTAACAGTCCG-3’, -actin 
rev 5’- TGGAATCCTGTGGCATCCATGAAAC-3’; FLIP fwd 5’-CGTCTCCTGCCTTGCTTCAG-
3’, FLIP rev 5’-CGAACCCAGACACTGCACAA-3’; XIAP fwd 5’-CTGAGTATATCCATGTCC-3’, 
XIAP rev 5’-ATGCAGAATGGTCAGTAC-3’; BclXL fwd 5’-TTCGGGATGGAGTAAACTGG-3’, 
BclXL rev 5’-TGCAATCCGACTCACCAATA-3’; Bax fwd 5’-CCCCAGTTGAAGTTGCCATC-3’, 
Bax rev 5’-GTTTCATCCAGGATCGAGCAG-3’. Reactions were performed in triplicate using a 
BioRad iCyclerTM with the following cycling conditions: 5 min at 50 oC, 2 min at 95 oC, 40 cycles of 
15 sec 95 oC and 1 min 60 oC.  Melting curves were performed after completion of each experiment.  
Relative fold change in gene expression was calculated by 2-(CT), where CT is [CT(target gene) - 
CT(recA)]mutant - [CT(target gene) - CT(recA)]wild type, CT being the threshold cycle. 
 Sequence alignment.  S. iniae genomic sequence data was obtained from Human Genome 
Sequencing Center at Baylor College of Medicine.  Sequences for the CpsY orthologs MtaR of S. 
agalactiae A909 (YP_329877), MetR of S. mutans UA159 (AAN58910), CpsY of S. pyogenes 
(NP_269094) and CpsY of S. iniae (AAY17292), as well as the nucleotide promoter sequence 
immediately upstream of atmB (metQ1) of S. agalactiae A909 (YP_330257), S. mutans UA159 
(AAN59551) and S. pyogenes (NP_268657) were obtained from GenBank.  Sequences were aligned 
and plotted using ClustalX through the Mobyle portal (http://mobyle.pasteur.fr/cgi-bin/portal.py) 
(216). 
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Macrophage adherence, internalization and survival assays.  The RAW 264.7 murine 
macrophage cell line (242) was maintained in 75 cm2 cell culture flasks (Corning) in Dulbecco’s 
Modified Eagle’s Medium (DMEM; Gibco) containing 10% heat-inactivated fetal bovine serum (FBS; 
Gibco) at 37 oC with 5% CO2.  Macrophage infection assays were performed in 24 well flat bottom 
plates (Greiner bio-one).  One day prior to each assay, macrophages were seeded at a density of 0.5 x 
106 cells per well in 1 ml DMEM with 10% FBS medium.  When required, macrophages were 
activated with 100 U ml-1 of murine IFN- at 1.5 hr post-seeding.  After overnight incubation, cell 
culture medium was removed and macrophages were washed 3 times with PBS.  Mid-exponential 
phase bacteria were diluted 1:100 into 1 ml DMEM with 10% FBS medium, which was then added to 
cells at an MOI of 1 (bacteria:cells).  The plates were centrifuged for 5 min at 250 x g to allow for 
contact between bacteria and the cell monolayer.  After 1 hr, cell culture medium was removed, and 
macrophages were washed 5 times with 1 ml of PBS for removal of any non-adherent bacteria.  For 
adherence assays, the cells were lysed in 1 ml sterile ddH2O and 100 l was serially diluted and plated 
on THY agar for enumeration of bacterial CFU, which represents both adhered and internalized 
bacteria.  For internalization and survival assays, infected cells were incubated with 1 ml fresh DMEM 
with 10% FBS containing 100 g ml-1 gentamicin (Gibco) for 1 hr to kill all extracellular bacteria.  
After the 1 hour incubation, cells were washed 3 times with PBS.  For internalization assays, cells were 
lysed in 1 ml sterile ddH2O and 100 l was removed, serially diluted and plated on TP agar for 
enumeration of surviving intracellular bacteria.  For survival assays, 1 ml of fresh DMEM with 10% 
FBS was added, which was then considered to be the 0 hr time point.  At specified times supernatants 
were collected, cells were washed 3 times in PBS and lysed in 1 ml sterile ddH2O.  One hundred 
microliters of supernatants and lysates were serially diluted and plated on THY agar for enumeration 
of bacterial CFU.  Final adherence numbers were calculated by (adhered: internalized CFU) – 
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(internalized CFU).  All infections were performed in duplicate and each experiment was repeated 3 
times.   
Fluorescent microscopy for macrophage viability.  To assess cell viability, macrophage 
infections were carried out as described above except circular glass coverslips were placed in each well 
prior to macrophage seeding.  At specified time points, culture medium was removed and cells were 
gently washed 3 times in 1 ml sterile 0.9% NaCl.  The LIVE/DEAD® BacLightTM kit (Invitrogen) was 
used to visualize cell viability per manufacturer’s instructions.  Briefly, 1 ml of 0.9% saline with 3 l 
of an equal mixture of SYTO 9 dye and propidium iodide was added to the cells in the 24 well plate, 
and incubated at room temperature in the dark for 15 minutes.  The coverslips were then carefully 
removed from the wells and gently placed cell side up onto glass microscope slides, immersed in 
BacLightTM mounting oil, and covered with a final glass coverslip.  Prepared slides were photographed 
by fluorescence microscopy using an Axioskop 40 microscope (Carl Zeiss, Inc.) fitted with an 
AxioCam MRc camera. 
Macrophage apoptosis assay.  Macrophages were infected as above with either live bacteria 
or culture supernatants collected from growth during mid-logarithmic phase.  Culture supernatants 
were filtered through an 0.2 micrometer filter, and either fractioned using a 50 kDA or 100 kDa cutoff 
centrifugal filter unit (Amicon) or treated with 1 mg ml-1 proteinase K (Sigma) in 10 mM Tris Hcl, pH 
7.5 buffer for 2 hr at 37 oC when required.  At 21 hr post-infection, 0.3 M staurosporine (Sigma) or 1 
M camptothecin (Sigma) was added for 3 hr to induce apoptosis.  At 24 hr post-infection induction of 
apoptosis was determined by measuring caspase 3 activity using the EnzChek Caspase 3 Assay Kit # 2 
(Invitrogen/Molecular Probes) per manufacturer instructions. 
Whole blood survival.  Heparinized human whole blood was collected by venipuncture.  
When required, cytochalasin D (Sigma) was added to a final concentration of 10 g ml-1 30 min. prior 
to incubation with bacteria.  Mid-exponential phase bacterial cultures were adjusted to 1 x 104 CFU ml-
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1, inoculated 1:100 in 1 ml whole blood, and incubated for 3 hours at 37 °C with gentle rotation.  One 
hundred microliters was serially diluted and plated on THY agar for enumeration of bacterial survival. 
All infections were performed in duplicate and each experiment was repeated 3 times. 
Neutrophil infections.  Human polymorphonuclear leukocytes, or neutrophils, were isolated as 
follows.  Heparinized human whole blood was collected by venipuncture and mixed in equal volume 
with 3% dextran (MP Biomedicals) in saline using 50 ml conical tubes.  Red blood cells were allowed 
to sediment out and the supernatant was centrifuged for 10 min at 800 x g at 4 oC to pellet the 
remaining cellular fraction.  Pellets were resuspended in 35 ml 0.9% NaCl and a 10 ml underlay of 
Ficoll-Paque (GE Healthcare) was applied.  This was centrifuged for 30 min at 410 x g in a hanging 
bucket rotor at room temperature to separate out the granulocyte fraction.  The supernatant was gently 
aspirated down to the loose pellet of granulocytes and erythrocytes.  Remaining erythrocytes were 
lysed by resuspension of the pellet with 10 ml sterile H2O for 28 seconds and isotonicity was quickly 
restored with 10 ml 1.8% NaCl.  Purified neutrophils were pelleted by centrifugation at 500 x g and 
resuspended in 3 ml DMEM.  Neutrophil concentration was determined by hemocytometer count.  
For infections, neutrophils were diluted to a final concentration of 1 x 106 cells ml-1 in DMEM 
with 50% human serum.  When required, neutrophils were pretreated 30 min prior to addition of 
bacteria with 10 g ml-1 cytochalasin D (Sigma) at 37 oC with gentle rotation.  For experiments 
requiring heat-inactivated serum, human serum samples were incubated at 55 oC for 30 min prior to 
neutrophil addition.  Mid-exponential phase cultures were washed twice in PBS and diluted to 1 x 105 
CFU ml-1 in PBS.  Ten microliters was inoculated into a 1 ml neutrophil suspension or media alone 
using 1.5 ml microcentrifuge tubes. Samples were incubated at 37 °C for 3 hr with gentle rotation.  
One hundred microliters of the sample was serial diluted and plated on THY agar for enumeration of 
bacterial survival.  In parallel, 100 l of the same sample was loaded into a cytology funnel (Thermo), 
centrifuged onto glass slides for 3 min at 700 rpm in a Cytospin 1 centrifuge (Shandon Elliott) and 
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stained using the HEMA 3 stain set (Fisher Scientific).  Slides were viewed with an Axioskop 40 
microscope (Carl Zeiss, Inc.) fitted with an AxioCam MRc camera. 
Statistical analysis.  A statistical analysis for all functional tests was performed by two-tailed 
Student's t test using StatView analysis software. 
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Results 
CpsY influences growth in vitro.   Previous work demonstrated that disruption of the CpsY 
ortholog MtaR in S. agalactiae results in a significant growth defect in human plasma that can be 
rescued with excess methionine (42, 259).  To determine if this same phenotype existed in S. iniae, 
both the WT and the cpsY mutant were cultured in human serum supplemented with and without 400 
g ml-1 L-methionine.  Growth of the cpsY mutant paralleled that of WT for the first 3 hours in serum 
alone, after which a significant drop in the growth rate resulted in approximately 1.5 log fewer CFU 
ml-1 recovered by 6 hr (Fig 3).  This attenuation could not be rescued with excess methionine.  The 
additional methionine had no influence on the growth of WT S. iniae consistent with previous reports 
for S. agalactiae (259). 
 To determine whether this same methionine-independent growth attenuation of the cpsY 
mutant translated to other media, growth was examined in THY both, a complex medium containing 
neopeptone, beef heart infusion, yeast extract and dextrose as a carbon source.  In this medium, the 
cpsY mutant exhibited a similar pattern to growth in serum, demonstrating a significant drop after 3 
hrs, which was independent of methionine (Fig. 4A).  However when cultured in C-medium, a medium 
containing yeast extract and 0.5% proteose peptone 3 but no dextrose, the cpsY mutant grew identical 
to WT (Fig. 4B).  This identical growth pattern was due to a decrease in cell density at stationary phase 
of the WT in C-medium compared to THY, and not due to an enhancement in the growth of the cpsY 
mutant.  Again, the addition of excess methionine had no effect on growth of either WT or the cpsY 
mutant.  Because C-medium contains proteose peptone 3, we supplemented THY broth with 2% 
proteose peptone #3 and monitored growth of WT and the cpsY mutant.  Adding peptone drastically 
extended exponential growth of the cpsY mutant reaching a final cell density over 2.5 times greater 
than without peptone (Fig 5A).  This was contrasted by the minimal change in growth observed for 
WT S. iniae in the presence of peptone (Fig. 5A).  A similar trend was observed for growth of the two 
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Figure 3.  Serum growth curves.  Mid logarithmic phase cultures of S. iniae WT along with the cpsY 
mutant were diluted into 1 ml DMEM 50% human serum with (+) or without  400 g ml-1 L-
methionine.  Samples were incubated at 37 oC and bacterial CFU were determined at the indicated time 
points by serial dilution and plating on THY.  Error bars represent  standard error.   *p < 0.05 
compared to WT.  
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Figure 4.  Effect of methionine on bacterial growth.  Overnight cultures of S. iniae WT and the cpsY 
mutant were diluted 1:50 into 200 l of THY (A) or C-medium (B).  When required, medium was 
supplemented with 400 g ml-1 L-methionine (+).  Samples were incubated at 37 oC and OD600 
measurements were recorded every 30 min. A representative experiment is shown.  Error bars 
represent  standard error.   *p < 0.05 compared to WT. 
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Figure 5.  Effect of proteose peptone on bacterial growth.  Overnight cultures of S. iniae 9117 WT and 
the cpsY mutant were diluted 1:50 into 200 l of THY (A) or C-medium (B).  When required, the 
medium was supplemented with 2% proteose peptone #3 (+).  Samples were incubated at 37 oC and 
OD600 measurements were recorded every 30 min.  A representative experiment is shown.  Error bars 
represent  standard error.   *p < 0.05 compared to WT.  
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strains in C-medium although growth phenotypes were not as severe (Fig. 5B).  This suggests that WT 
S. inaie can manage the excess nutrients supplied in peptone with minimal effect on normal growth 
patterns, whereas the cpsY mutant displays a type of unrestrained exponential growth.  Overall the 
data indicate that CpsY influences the growth patterns of S. iniae in a methionine-independent manner.   
CpsY regulation of methionine metabolic pathways.  The S. iniae CpsY protein shares 79% 
amino acid sequence identity to the orthologs MtaR of S. agalactiae and MetR of S. mutans.  Both 
MtaR and MetR have been shown to regulate genes involved in methionine biosynthesis and uptake 
(259, 268).  Thus we hypothesized that the insensitivity to methionine on growth of the cpsY mutant 
may be due to differences in these metabolic pathways.  To address this hypothesis the genomes of S. 
iniae and several other streptococcal species were examined by BLAST analysis for the presence of 
genes involved in the biosynthesis and uptake of methionine as previously described for S. mutans 
(Fig. 6) (268).  Neither S. iniae nor S. agalactiae possess the full complement of genes required for de-
novo methionine biosynthesis from cysteine (Table 1); however, all streptococcal species investigated 
were found to contain the AtmBDE (MetQ1NP) methionine transport system.  Additionally, S. 
agalactiae contains the genes encoding MetE and MetF for conversion of homocysteine to methionine.  
S. iniae does not possess metE or metF, and thus appears to be purely auxotrophic for methionine.   
The methionine-dependent growth defect of the S. agalactiae mtaR mutant was attributed to the 
inability to effectively transport exogenous methionine due to reduced expression of the MetQ1NP 
methionine transport system (42, 259).  Although exogenous methionine could not rescue growth of 
the S. iniae cpsY mutant (Fig. 4), the role of CpsY in regulation of the AtmBDE locus was still in 
question.  Quantitative PCR (qPCR) was performed to assess CpsY-dependent regulation of the atmB 
gene under various growth conditions.  When cultured in THY broth to either mid-logarithmic or 
stationary phase, there was < 2 fold change in gene expression for the cpsY mutant relative to WT 
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Figure 6.  Schematic of streptococcal methionine biosynthesis and uptake pathways.  The pathways 
represented were previously characterized for S. mutans (50).   Genes present in S. iniae as determined 
by BLASTP analysis are shown in black, while genes absent are in grey.  Gene designations are listed 
in Table 1.  SAM, S-adenosylmethionine; SAH, S-adenosylhomocysteine; SRH, S-
ribosylhomocysteine; MET, Methionine; AI2, Autoinducer 2. 
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  Table 1. Orthologs of the methionine metabolism and transport pathways. 
  Gene Function Sina Spya Saga Smua
  cysE Serine acetyltransferase + + + + 
  cysK Cysteine synthase + + + + 
  metI Cystathionine -synthase 0 0 0 + 
  metC Cystathionine -lyase + + + + 
  metB Homoserine O-succinyltransferase 0 0 0 + 
  metY O-acetylhomoserine sulfhydrylase 0 0 0 + 
  metE Methionine synthase 0 0 + + 
  metF 5,10-methylenetetrahydrofolate reductase 0 0 + + 
  metK S-adenosylmethionene synthase + + + + 
  pfs Methylthioadenosine nucleosidase + + + + 
  luxS S-ribosylhomocysteinase + + + + 
  atmB ABC transporter, Substrate binding protein + + + + 
  atmD ABC transporter, ATP binding protein + + + + 
  atmE ABC transporter, Permease + + + + 
 
a Species designations are as follows: Sin, Streptococcus iniae 9117; Spy, Streptococcus pyogenes M1 
GAS; Sag, Streptococcus agalactiae A909; Smu, Streptococcus mutans UA159.  Symbol designations 
are (+) for the presence or (0) for absence of the gene as determined by BLASTP using genes 
previously identified in S. mutans. 
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Table 2. Relative atmB expression for cpsY 
Mediaa Growth Phase atmBN relative to WTb 
THY mid logarithmic 0.585 ± 0.17 
THY stationary 1.154 ± 0.14 
THY + MET mid logarithmic 0.349 ± 0.03 
THY + HC mid logarithmic 1.302 ± 0.03 
THY + MET stationary 0.288 ± 0.05 
THY + HC stationary 0.857 ± 0.04 
TP mid logarithmic 2.607 ± 0.49 
TP stationary 1.280 ± 0.53 
 
 
 
 
 
 
 
 
 
aAddition of 4 mM L-methionine (MET) or homocysteine (HC) for 30 min. 
bRelative fold change (N) as determined by the CT method. 
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(Table 2).  However, addition of 4 mM exogenous methionine for 30 min at mid-logarithmic or 
stationary phase resulted in a relative decreased expression of over 2.5 and 3.5 fold respectively.  This 
suggests that CpsY is a transcriptional activator of atmB in the presence of methionine.  Addition of 
exogenous homocysteine, however, had minimal effect on atmB gene expression.   In contrast to these 
observations, addition of 2% proteose peptone (TP) resulted in 2.5 fold increased expression of atmB 
relative to WT during mid-log phase, but not stationary phase.  Thus CpsY functions as a 
transcriptional activator of atmB in the presence of exogenous methionine; however, the presence of 
proteose peptone disrupts this regulation, suggesting other regulatory elements may be involved. 
Transcriptional control of atmB by CpsY orthologs is proposed to occur through interactions 
with a specific promoter element termed the Met box (42, 248, 268).  Sequence alignment of the atmB 
promoter region in S. iniae to several other streptococcal species revealed the presence of a Met box in 
the same position upstream of the predicted -10, -35 sites (Fig. 7).  Overall the data are concurrent with 
the proposed regulation of the AtmBDE methionine transporter for other streptococcal species.  
However, this regulation does not explain how CpsY influences S. iniae growth given that exogenous 
methionine does not rescue the cpsY mutant in vitro.  Thus, CpsY may have pleiotropic effects on S. 
iniae that extend beyond regulation of methionine metabolism, which has also been suggested for S. 
agalactiae (42).  
CpsY facilitates S. iniae tissue specific localization within macrophages.  During previous 
studies of S. iniae, CpsY was found to be essential for systemic infection in a zebrafish model (185).  
Whereas wild type (WT) S. iniae could disseminate rapidly to the brain following intramuscular 
injection, the cpsY mutant displayed an inability to efficiently spread beyond the spleen (185).  Thus, 
we sought to determine a more specific function for CpsY during the course of systemic infection.  
Adult zebrafish were infected with WT S. iniae or the cpsY mutant by intramuscular injection, and 
systemic organs were harvested 24 hr post-infection for histological analysis.  Visual examination of  
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Figure 7.  Promoter alignment for the atmBDE cluster.  Sequences obtained from GenBank were 
aligned and plotted using ClustalX.  The previously determined S. mutans transcriptional start site (50) 
is in bold, predicted -10 and -35 sites are underlined, translational start codon is italicized, and 
predicted Met boxes are shaded. Sag, S. agalactiae A909; Spy, S. pyogenes M1; Sin, S. iniae 9117; 
Smu, S. mutans UA159. 
 
 
 
 
 
 
Sag -TATAGTTTAAAACTATA-N22-TTGATT-N16-GATAAT-N8-C-N22-ATG 
Spy -TATAGTTTAAAACTATG-N22-TTGAAA-N17-TACAAT-N6-C-N28-ATG 
Sin -TATAGTTTAAAACTATA-N22-TTGATA-N17-TAGAAT-N5-C-N24-ATG 
Smu -TATAGTTTTTAGCTATA-N22-TTGATA-N16-GAGAAT-N7-C-N24-ATG 
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Figure 8.  Images of tissue homogenates from S. iniae-infected zebrafish.  Zebrafish were injected i.m. 
with 105 CFU of either S. iniae WT or the cpsY mutant.  Zebrafish spleens (A) or brains (B) were 
dissected 24 hours post-infection, gently homogenized in PBS, cytocentrifuged on to glass slides and 
stained for visualization.  Two representative images for each condition are shown.   Black arrows 
depict examples of intracellular bacteria within macrophages.  Macrophage nuclei are noted with a 
white asterisk.  
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HEMA-stained cytospin preparations from spleen homogenates showed that both WT and the cpsY 
mutant were contained within macrophage phagosomal compartments (Fig. 8A).  For all infected fish 
(n = 6), the majority of splenic macrophages were filled with cocci with few extracellular bacteria 
observed.  In contrast, only WT could be detected in cytospin preparations of brain homogenates (Fig. 
8B).  Brain macrophage-like cells from cpsY-infected fish showed signs of activation with large 
empty phagosomal vacuoles, but contained no bacteria (Fig. 8B).    These results suggest that S. iniae 
localizes within tissue macrophages during the course of systemic infection, and that CpsY affects this 
localization within specific tissue environments.   
Intracellular survival in macrophages is independent of CpsY.  Because of the tissue 
specific macrophage localization observed in the zebrafish infection model, we sought to determine if 
S. iniae intracellular survival in macrophages was dependent upon CpsY.  The RAW 264.7 murine 
macrophage cell line (242) was used as an in vitro platform to evaluate streptococcal-macrophage 
interactions.  Macrophages were infected with either WT S. iniae or the cpsY mutant for 1 hr to allow 
for bacterial uptake, followed by a 1 hr gentamicin treatment to kill all extracellular bacteria.  Bacterial 
growth was then determined at various time points over the following 24 hrs.  No significant difference 
was observed between S. iniae WT and the cpsY mutant in macrophage cell lysates (Fig. 9A) or 
culture supernatants (Fig. 9B) at all time points tested.  The number of bacteria remained relatively 
constant at the 2 and 4 hour time points, and by 24 hr had increased over 3-logarithms.  Adherence and 
internalization assays also revealed no significant difference in bacterial uptake by macrophages (Fig. 
9C).  Furthermore, macrophage activation by pretreatment with IFN- resulted in no significant 
difference from untreated samples (Fig. 9).  S. iniae does not appear to be actively killing macrophages 
because viability staining of infected macrophages showed the majority of macrophages to be alive, 
intact and filled with bacteria through 48 hr (Fig. 10).  Overall these results indicate that CpsY does not  
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Figure 9.  S. iniae macrophage infections.  Raw 264.7 macrophages were infected at an M.O.I. of 1 
with WT (grey bars) or cpsY (white bars) as described in materials and methods.  At required time 
points culture supernatants were collected, cells were washed, and lysed in H2O.  Dilutions of the cell 
lysates (A) and culture supernatants (B) were serially diluted and plated for bacterial CFU.  For certain 
experiments, macrophages were activated by pretreatment with 100 U ml-1 of murine IFN- () for 24 
hr prior to infection with bacteria.  (C) Adherence (A) and internalization (I) assays were performed as 
described in materials and methods.  Error bars represent  standard error.  
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Figure 10.  Live/Dead® fluorescent staining of S. iniae-infected macrophages.  RAW 264.7 
macrophages were infected with S. iniae WT or cpsY as described in materials and methods.  At the 
indicated time points, cells were washed with 0.9% NaCl, and assayed for macrophage viability using 
the LIVE/DEAD® BacLightTM kit (Invitrogen) per manufacturer’s instructions.  White asterisk 
indicates the macrophage nucleus, and white arrows indicate S. iniae.  
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play an essential role during interactions with macrophages in vitro, and suggest an alternative role in 
S. iniae pathogenesis. 
Bacterial pathogen-associated molecular patterns prevent chemically-induced 
macrophage apoptosis in vitro.  Because S. iniae-infected macrophages remain viable though 48 hr 
post-infection, we sought to determine if this viability was a specific manipulation of the macrophage 
toward a pro-survival response, or if S. iniae simply was not actively killing the macrophage.  
Macrophages were infected as above for 24 hr, and assayed for the induction of apoptosis by 
measuring caspase 3 activity.  Macrophages infected with either S. iniae WT or the cpsY mutant 
displayed minimal caspase 3 activity over mock-infected cells at 24 hours post-infection (Fig. 11), 
indicating that S. iniae does not induce apoptosis of macrophages.  To determine whether S. iniae 
actively manipulates macrophages to protect against apoptosis, infected cells were treated with either 3 
M camptothecin (CAM) or staurosporine (STA) to induce apoptosis.  Mock-infected macrophages 
displayed a characteristic induction of caspase 3 activity in the presence of either inducer (Fig. 11).  In 
contrast, CAM or STA-treated macrophages infected with either WT or the cpsY mutant showed no 
caspase 3 activity above background level (Fig. 11).  The data suggest that S. iniae-infection of 
macrophages promotes a pro-survival response independent of CpsY, which can override the pro-
apoptotic induction signals provided by CAM and STA.  Quantitative PCR of S. iniae WT-infected 
macrophages revealed an increased expression of the pro-survival factors BclXL and FLIP, but a 
decreased expression of XIAP relative to mock treated macrophages (Fig. 12).  BclXL and FLIP act on 
components associated with the initial induction of apoptosis signaling cascades, while XIAP acts to 
directly inhibit caspase 3.  The data suggest that S. iniae induces a macrophage pro-survival response 
of specific apoptosis-related pathways upstream of caspase 3 activation.  
To assess whether the macrophage pro-survival state was induced by an S. iniae secreted factor, 
macrophages were pre-treated for 24 hr with filtered culture supernatants (0.2 micron filter) from mid-  
   
      46
 
 
 
 
 
 
 
0
20000
40000
60000
80000
100000
120000
140000
160000
180000
200000
Mock WT cpsY
R
FU
None
CAM
STA
 
 
 
Figure 11.  Macrophage apoptosis.  RAW 264.7 macrophages were infected with S. iniae WT, cpsY 
or mock infected as described in materials and methods.  At 21 hr post-infection cells were treated with 
0.3 M staurosporine (STA, light grey bars), 1 M camptothecin (CAM, dashed grey bars) or left 
untreated (black bars) for 3 hr to induce apoptosis.  At 24 hr post-infection induction of apoptosis was 
determined by measuring caspase 3 activity using the EnzChek Caspase 3 Assay Kit # 2 (Invitrogen).  
RFU, relative fluorescence units.   
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Figure 12.  qPCR of S. iniae-infected macrophages.  RAW 264.7 macrophages were infected with WT 
S. iniae and total RNA was isolated after 24 hours.  Relative fold change gene expression compared to 
mock infection was determined by the 2-CT method. 
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logarithmic phase growth, then treated with STA and assayed for caspase 3 activity as before.  As 
observed with live cells, S. iniae culture supernatants were also able to provide protection against  
STA-induced apoptosis (Fig. 13), suggesting that the pro-survival inducing factor is either actively 
secreted or is released from the outer surface of the cell during growth.  Using centrifugal filter units to 
fractionate the culture supernatants, the pro-survival inducing factor was determined to be > 100 kDa 
in size (Fig. 13).  A slight reduction in STA-induced caspase 3 activity was observed in the fraction < 
100 kDa suggesting that this factor may be a polymeric substance with subunits < 100 kDa (Fig. 13).  
A secreted or released substance of that size could be a large protein complex attached to the cell wall 
such as a pilus, or possibly related to the polysaccharide capsule.  To determine whether capsule was 
responsible for this phenomenon, the same macrophage treatments were performed with either live 
bacteria or filtered culture supernatants from both WT S. iniae and a cpsA-insertional mutant, which 
contains a defect in capsule production (185).  Macrophages treated with the cpsA-insertional mutant 
displayed no difference from WT treatment indicating that capsule was not involved (Fig. 14).  Similar 
observations occurred when culture supernatants were pre-treated with proteinase K to remove any 
proteins (Fig. 14).  Thus the pro-survival inducing factor appears to be a large proteinase K-resistant 
polymeric substance unrelated to capsule.  This prompted examination of culture supernatants from a 
variety of other Gram positive and Gram negative bacteria to determine if this factor was a shared 
substance from all microorganisms such as peptidoglycan.  Treatment of macrophages with filtered 
culture supernatants from S. iniae, S. aureus, Escherichia coli, Vibrio cholerae, Lactococcus lactis and 
S. agalactiae, as well as live E. coli was able to prevent STA-induced apoptosis (Fig. 15).  The data 
indicate that the observed macrophage pro-survival response is not specific to S. iniae, but rather is a 
programmed macrophage response to the presence of microorganisms under these conditions. 
CpsY is essential for S. iniae survival in whole blood.  Systemic dissemination from the 
initial infection site requires a pathogen to effectively enter and survive in the blood stream.  While in 
   
      49
 
0
20000
40000
60000
80000
100000
120000
140000
160000
180000
200000
Mock WT WT(S) <50K(S) >50K(S) <100K(S) >100K(S)
R
FU None
STA
Figure 13.  Macrophage apoptosis of S. iniae culture supernatant-treated cells.  S. iniae mid-log phase 
culture supernatants grown in THY were filtered on an 0.2 M filter, and fractioned using a 50 kDA or 
100 kDa cutoff centrifugal filter unit.  RAW 264.7 macrophages were either infected with WT S. iniae 
as before, treated with the filtered culture supernatants (S) or mock infected for 24 hours as described 
in materials and methods.  At 21 hr post-infection cells were treated 3 hr with 0.3 M staurosporine 
(STA, light grey bars) to induce apoptosis or left untreated (black bars).  At 24 hr post-infection 
induction of apoptosis was determined by measuring caspase 3 activity using the EnzChek Caspase 3 
Assay Kit # 2 (Invitrogen).  RFU, relative fluorescence units.   
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Figure 14.  Macrophage apoptosis. RAW 264.7 macrophages were infected with either WT S. iniae or 
a capsule-deficient mutant (cpsA), or treated with culture supernatants (S) from either strain for 24 
hours as before.   Additionally WT S. iniae supernatants were treated with proteinase K (ProK) for 3 
hours prior to macrophage treatment.  At 21 hr post-infection, cells were treated for 3 hr with 0.3 M 
staurosporine (STA, light grey bars) to induce apoptosis or left untreated (black bars).  At 24 hr post-
infection induction of apoptosis was determined by measuring caspase 3 activity using the EnzChek 
Caspase 3 Assay Kit # 2 (Invitrogen).  RFU, relative fluorescence units.   
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Figure 15.  Macrophage apoptosis of cells treated with culture supernatants from a panel of bacteria. 
RAW 264.7 macrophages were treated with mid-logarithmic phase filtered culture supernatants for 24 
hours as before.  At 21 hr post-treatment cells were treated for 3 hr with 0.3 M staurosporine (STA, 
light grey bars) to induce apoptosis or left untreated (black bars).  At 24 hr post-infection induction of 
apoptosis was determined by measuring caspase 3 activity using the EnzChek Caspase 3 Assay Kit # 2 
(Invitrogen).  RFU, relative fluorescence units.   Sin, Streptococcus iniae; Sau, Staphylococcus aureus; 
Eco, Escherichia coli; Vch, Vibrio cholerae; Lla, Lactococcus lactis; Sag, Streptococcus agalactiae. 
Eco*, live E. coli-treatment.   
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the blood stream a pathogen must withstand immune clearance by blood leukocytes.  Because the 
cpsY mutant was unable to disseminate to the brain, the requirement of CpsY for S. iniae survival in 
whole blood was investigated.  Both WT S. iniae and the cpsY mutant were incubated in human 
whole blood for 3 hr and serially diluted onto THY agar plates to determine bacterial survival.  WT S. 
iniae displayed an ability to replicate in whole blood, reaching levels approximately 2 logs over the 
inoculum (p < 0.05), while the cpsY mutant was almost completely killed under the same conditions 
(p < 0.05) (Fig. 16).  To determine if this difference in bacterial survival was due to phagocytic killing 
by blood leukocytes, whole blood was pretreated for 30 min with cytochalasin D (CD), an inhibitor of 
actin polymerization, to block phagocytosis.  The addition of CD completely rescued the cpsY mutant 
to WT levels (Fig. 16).  These results suggest that leukocyte phagocytic killing is the primary 
bactericidal force against the cpsY mutant, and indicate a function for CpsY in the regulation of 
factors required for protection of S. iniae from phagocytic clearance. 
CpsY protects S. iniae from neutrophil intracellular killing.  To confirm that blood 
leukocytes were responsible for the extensive killing of the cpsY mutant in whole blood, S. iniae WT 
and the cpsY mutant were incubated 3 hr in either 50% human serum alone or with the addition of 
primary peripheral blood neutrophils.  Significant growth was observed for both WT and the cpsY 
mutant in 50% human serum alone (p < 0.0001) (Fig. 17).  Addition of neutrophils resulted in a 
reduction of WT compared to serum alone (p = 0.0005) (Fig. 17), which was still significant growth 
over the inoculum (p < 0.0001).  In contrast, the cpsY mutant was highly attenuated with the addition 
of neutrophils (p = 0.0001 compared to serum alone) (Fig. 17).  Pretreatment of the neutrophils with 
CD rescued both WT and the cpsY mutant back to the levels observed in serum alone (Fig. 17), 
confirming the phenotype found in the whole blood. 
HEMA-stained cytospin slide preparations of infected neutrophils (in 50% human serum) 
revealed intracellular localization of both WT and the cpsY mutant within a vacuole (Fig. 18).  
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Figure 16.  S. iniae survival in human whole blood.  Mid-log phase cultures of S. iniae WT (grey bars) 
or cpsY (white bars) were diluted into 1 ml heparinized human whole blood, and incubated at 37 oC 
with gentle rotation.  Samples were serially diluted and plated on THY for enumeration of bacterial 
CFU.  For certain conditions blood was pretreated for 30 min with 10 g ml-1 cytochalasin D (CD).  
Error bars represent  standard error.   *p < 0.05 compared to WT.  
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Figure 17.  S. iniae neutrophil infections.  Mid-logarithmic cultures of S. iniae WT (grey bars) or 
cpsY (white bars) were diluted 1 ml DMEM 50 % human serum.  When necessary, human primary 
neutrophils (N) were added to a final MOI of 0.001 (bacteria:neutrophil).  If required, neutrophils were 
pretreated with 10 g ml-1 cytochalasin D (CD) for 30 min.  Samples were incubated at 37 oC with 
gentle rotation, followed by serial dilution and plating on TP for enumeration of bacterial CFU.    Error 
bars represent  standard error.  * p < 0.01, ** p = 0.0001 compared to WT.  
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Figure 18.  Images of S. iniae neutrophil infections.  S. iniae WT or cpsY were mixed with 
neutrophils suspended in 1 ml DMEM with 50 % serum alone, with cytochalasin D pretreatment (CD), 
or with 50 % heat-inactivated serum (HIS).  After 3 hrs 100 l of the sample was cytocentrifuged on to 
glass slides and stained for visualization.  A representative image for each condition is shown.   Black 
arrows depict bacteria.  Cell nuclei are noted with a white asterisk.  
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Pretreatment with CD completely inhibited phagocytosis, but the bacteria remained closely associated 
to the neutrophil outer surface (Fig. 18).  Similar observations were made when serum was heat 
inactivated prior to infection (Fig. 18).  Thus, cpsY is not involved in preventing phagocytic uptake, but 
rather must function to protect S. iniae within the neutrophil phagosome. 
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Discussion 
Bacteria have a variety of mechanisms for maintaining the required supply of nutrients needed 
for survival in nutrient-limited environments by either de-novo synthesis or nutrient scavenging from 
the external environment.  While many of these pathways are functionally conserved in both Gram-
positive and Gram-negative bacteria, others differ markedly even within the same genera.  
Streptococcal species appear to use the same general pathway for managing intracellular methionine 
supply, although portions of the pathway appear to be missing in some species (Table 1). 
The current collection of information on the streptococcal CpsY regulon is focused on its role 
in methionine metabolism and uptake (259, 268). De-novo biosynthesis of methionine begins with the 
generation of homocysteine through transsulfuration (MetB, MetI, MetC), direct sulfhydrylation 
(MetB, MetY) or S-adenosylmethionine (SAM) recycling (MetK, Pfs, LuxS) pathways (Fig 6).  
Homocysteine is then converted to methionine by the cobalamin-independent methionine synthase 
(MetE) and 5,10-methylenetetrahydrofolate reductase (MetF) (268).  Portions of these pathways are 
incomplete in S. iniae, S. agalactiae and S. pyogenes (Table 1) (248) and in these pathogens 
incomplete de-novo biosynthesis is thought to be balanced by environmental methionine scavenging 
through the conserved AtmBDE (MetQ1NP, also called Abc,YaeEC) ABC transport system (248).   
A comprehensive understanding of how streptococci regulate their repertoire of methionine 
metabolic genes is still emerging.  In Gram negative organisms, the MetJ repressor along with the 
SAM cofactor controls transcription of the de novo methionine biosynthesis genes and the atmBDE 
locus when methionine levels are sufficient (169).  Repression is relieved under sulfur limiting 
conditions when methionine biosynthesis is required (113).  In addition, the CpsY ortholog MetR 
utilizes homocysteine as a cofactor to compete with the MetJ:SAM complex and increases methionine 
biosynthesis through transcriptional activation of metE and metF when methionine levels are 
insufficient (47, 65, 183, 234, 290-291).   
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MetR is thought to be the primary regulator of methionine biosynthesis and uptake pathways 
for streptococcal species due to the absence of a MetJ ortholog (158).  In S. mutans, MetR-dependent 
activation of metE and atmBDE occurs under methionine-limitation but not excess (268).  Expression 
of metE and atmB can be triggered in the presence of excess methionine only if excess homocysteine is 
also present in the medium, because homocysteine is the activating co-factor for MetR (268).  In S. 
agalactiae, MtaR was shown to activate metQ1 (atmB) in the presence of excess methionine, but had 
no effect on metE expression (42).  The effect on metQ1 or metE in the absence of methionine was not 
investigated in that study.  S. iniae does not carry the metE or metF genes, but does contain genes 
encoding the AtmBDE transporter.  We show here that a CpsY-dependent increase in atmB expression 
occurs in the presence of excess methionine, but not homocysteine.  Thus as observed in other species, 
CpsY appears to increase cellular methionine pools through transcriptional activation of the AtmBDE 
transport system; however, the environmental condition under which this occurs differs between 
species.  Those species which contain a complete de novo methionine biosynthesis pathway (i.e. S. 
mutans) limit expression of atmB in the presence of excess methionine and respond to homocysteine, 
whereas those with incomplete pathways (i.e. S. iniae) increase expression of the transporter and do 
not respond to homocysteine.  This difference is not due to alterations in the promoter structure 
because a canonical Met box (TATAGTTTnAAACTATA) was found in the same proximal location to 
atmB in all species.   This may possibly be due to differences in CpsY itself or additional regulatory 
elements that function either in cis or in trans to influence the regulation of this locus. 
The physiological explanation for these observed differences in S. iniae has yet to be 
determined, but may be due in part to the absence of both MetE and MetF for conversion of 
homocysteine to methionine.  This conversion is a key step in recycling of the primary methyl donor 
SAM (307).  An inability to convert homocysteine back to methionine due to the absence of MetEF 
would necessitate methionine scavenging for generation of SAM.  Thus S. iniae may have evolved 
alternate regulatory mechanisms to compensate for the lack of MetEF.  S. pyogenes, S. uberis and S. 
   
      59
equi also do not have the metEF genes (158), but whether their respective CpsY orthologs function 
similar to S. iniae is unknown. 
A systemic pathogen must adapt to one or more environments in the host and, as has been 
shown for many pathogens, these adaptations involve metabolic changes. The work presented here 
demonstrates a specific role for CpsY during S. iniae systemic infection.  In addition to control of 
methionine transport through regulation of the atmB gene, CpsY is critical for adaptation and survival 
in the intracellular environment of neutrophils in whole blood.  The enhanced susceptibility of the 
cpsY mutant to neutrophil-mediated killing correlates with the attenuation initially observed in our 
zebrafish infection model (185). 
While CpsY is absolutely required for S. iniae survival in neutrophils, it appears dispensable 
for survival in macrophages.  This is supported in vivo where localization of S. iniae within splenic 
macrophages of infected zebrafish is independent of CpsY.  Contradictory was the observation that 
intracellular localization within zebrafish macrophage-like cells in the brain is dependent upon CpsY.  
An explanation for this dichotomy in vivo may be that the ability to survive and replicate in the blood 
stream is a precursor for the establishment of a CNS infection (43, 84, 240, 318).  Thus, the inability of 
the cpsY mutant to localize within brain macrophages could be due to limited bacteremia in vivo, and 
not susceptibility to macrophage-mediated killing within the brain.  If the cpsY mutant were rapidly 
cleared in the blood stream by neutrophils, then a decrease in the bacterial load at distant sites would 
be expected.  This explanation correlates with previous reports where the cpsY mutant displayed a 
unique inability to acutely disseminate to the brain 30 minutes post intramuscular infection, while 
bacterial loads in the spleen were equal to WT (185).  Neutrophils are the primary phagocytic cell 
found in the blood stream, and are vital for protection from invading pathogens (175).  The ability to 
exploit the host inflammatory response and survive within neutrophils is an important virulence trait of 
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several pathogens including Staphylococcus aureus (110), Streptococcus pyogenes (196), 
Streptococcus suis (306) and Listeria monocytogenes (81). 
Mutations in orthologs of CpsY have been shown to influence growth in vitro due to the 
disruption of methionine supply described above.  This defect could be rescued with the addition of 
exogenous methionine for S. agalactiae (42, 259) and S. mutans (268), but as shown here, not for S. 
iniae.  In contrast, addition of 2% proteose peptone resulted in unrestricted exponential growth for the 
cpsY mutant while growth of the WT strain was unaffected.  The data suggest that in S. iniae, CpsY 
functions to maintain proper growth in vitro in a way that differs from S. agalactiae or S. mutans.   The 
inability of the cpsY mutant to maintain proper growth in vitro does not appear to be the cause of its 
virulence attenuation.  The cpsY mutant was highly attenuated in whole blood, but was able to grow 
to WT levels upon inhibition of neutrophil phagocytosis by the addition of CD.  Thus the attenuation 
observed in whole blood is not due to a growth defect, but specifically the inability to survive 
neutrophil phagocytosis.  The sensitivity to phagocytosis is specific to neutrophils because growth in 
macrophages was unaltered.  Overall the data suggest that CpsY provides a unique virulence function 
that allows S. iniae to adapt for intracellular survival within neutrophils.  The growth disparity 
observed for the cpsY mutant in vitro appears to reflect an early entry into stationary phase, which 
could suggest a defect in cell wall biosynthesis, cell stress response pathways or autolysin regulation 
rather than an auxotrophic phenotype (245). 
CpsY orthologs have also been implicated in the regulation of genes unrelated to methionine 
acquisition.  S. agalactiae MtaR affects the expression of a cell surfaces protease (cspA) and fibrinogen 
binding protein (fsbB) implicated in streptococcal pathogenesis, as well as numerous genes involved in 
arginine transport and sugar metabolism (42).  In Pseudomonas aeruginosa, MetR has significant 
effects on swarming motility in semi-viscous media, and was shown to control several transcriptional 
regulators, a Type III secretion system, as well as pyoveridine and pyochelin synthesis genes (312).  
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Furthermore, MetR in Vibrio harveii was shown to act directly on the luxCDABE operon to repress 
luminescence independent of the quorum sensing AI1 and AI2 signal levels (57). 
The data presented here demonstrate that CpsY has a pleiotropic regulatory effect on S. iniae 
pathogenesis that extends beyond the traditional methionine metabolic processes.  Furthermore, CpsY 
may have been co-opted to provide regulatory input on virulence gene expression based on the 
nutritional status of the cell.  Moreover, S. iniae provides a unique model to investigate the paradigm 
of CpsY-dependent regulation during systemic streptococcal infection due to the absence of a 
methionine-dependent growth deficiency. 
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CHAPTER 3 
CpsY-dependent protection from neutrophil-mediated killing involves modification 
and stabilization of the Streptococcus iniae cell wall 
 
Abstract 
The ability of a pathogen to evade neutrophil phagocytic killing mechanisms is critically 
important for dissemination and establishment of a systemic infection.  Understanding how pathogens 
overcome these innate defenses is important for the development of optimal therapeutic strategies for 
invasive infections.  CpsY is a conserved transcriptional regulator previously identified as an important 
virulence determinant for systemic infection of Streptococcus iniae.  While orthologs of CpsY have 
been associated with the regulation of methionine metabolism and uptake pathways, CpsY additionally 
functions in protection from neutrophil-mediated killing.  S. iniae does not alter neutrophil phagosomal 
maturation, but instead is able to adapt to the extreme bactericidal environment of a mature neutrophil 
phagosome dependent upon CpsY.  This CpsY-dependent adaptation appears to involve stabilization 
of the cell wall through peptidoglycan O-acetylation and repression of cellular autolysins.  In addition, 
CpsY may influence these processes by responding to nutritional stress..  Furthermore S. iniae proves 
to be a powerful model to investigate bacterial adaptations during systemic streptococcal infection. 
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Introduction 
The ability of a systemic pathogen to evade or manipulate the host innate immune response is a 
key factor in determining the severity of a bacterial infection (289).  Polymorphonuclear leukocytes 
(neutrophils) are a primary bactericidal force against invading bacteria, and represent a formidable 
obstacle for pathogens to overcome (33).  This is especially reflected in the susceptibility of patients 
with inherited neutrophil disorders to severe bacterial infections (191).  Neutrophils are efficient at 
eliminating invading pathogens through both intracellular (256) and extracellular killing mechanisms 
(222).  Engulfed pathogens suffer a barrage of bactericidal attacks from exposure to reactive oxygen 
and nitrogen species (172, 256), antimicrobial peptides (104, 241), proteases (48, 250, 264) 
peptidoglycan degrading enzymes (211), and metal deprivation (135, 154, 217). 
Invasive pathogens have evolved several strategies for evasion of neutrophil killing 
mechanisms.  Pathogens attempt to avoid phagocytic uptake through prevention of opsonin deposition 
(282) and production of a polysaccharide capsule (179).  Engulfed pathogens can either disrupt 
phagosomal maturation, escape into the cytoplasm or adapt for survival within the mature phagosome 
(289).  Adaptive processes for phagosomal survival occur in part through chemical modification of 
outer surface structures including lysinylation of lipid membranes (92, 162, 251), D-alanylation of wall 
teichoic acids (55, 100) and O-acetylation of N-acetylmuramyl peptidoglycan residues (20-21, 68). 
Streptococcus iniae is an invasive pathogen of aquatic species that causes severe bacteremia 
and meningoencephalitis (4, 88-89).  The rapid dissemination of S. iniae to systemic sites reflects its 
ability to survive and replicate in the blood stream (43, 101, 185).  CpsY is a conserved transcriptional 
regulator previously identified as an important virulence determinant for systemic infection of S. iniae 
(185), and mutants of cpsY are specifically susceptible to neutrophil-mediated killing in whole blood 
(Fig. 16).  CpsY is orthologous to the MetR transcriptional regulator associated with methionine 
metabolism and uptake pathways in Gram negative and Gram positive microorganisms.  MetR 
increases cellular methionine pools in Streptococcus mutans and Streptococcus agalactiae through 
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transcriptional activation of both an ABC transport system and methionine synthase (MetE) (42, 268).  
Mutants of metR in these species display a severe growth defect and require exogenous methionine for 
optimal growth (42, 268).  S. iniae does not contain an ortholog of metE, but CpsY does function as a 
transcriptional activator of the methionine ABC transporter.  In contrast to S. mutans and S. agalactiae, 
however, the effect of CpsY on growth of S. iniae is independent of exogenous methionine.  Rather, a 
strain deleted for the cpsY gene (cpsY) displays aberrant growth patterns, with final cell densities at 
stationary phase reaching levels either significantly greater or less than WT dependent upon media 
conditions.  Furthermore, growth of the cpsY mutant could not explain the severe susceptibility to 
neutrophil-mediated killing in whole blood.  Thus the CpsY regulon must allow S. iniae to specifically 
adapt for intracellular survival in neutrophils by a previously undetermined mechanism. 
This work elucidates the role of CpsY for S. iniae intracellular survival in neutrophils.  S. iniae 
does not appear to disrupt neutrophil phagosomal maturation, instead the CpsY regulon protects S. 
iniae from the bactericidal components contained within a mature phagosome.  This protection appears 
to be mediated in part by modifications to the peptidoglycan cell wall and repression of streptococcal 
autolysins.  Furthermore, we discuss how CpsY-dependent regulation of methionine supply pathways 
may influence these processes. 
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Materials and Methods 
Bacterial strains, media and culture conditions.  The parent S. iniae strain 9117 and a cpsY 
in-frame deletion mutant (cpsY) used in this study have been described previously (185).  All plasmid 
constructs were propagated using Escherichia coli TOP10 cells (Invitrogen) cultured in Luria-Bertani 
(LB) medium. Streptococcal strains were cultured in Todd-Hewitt broth (BBL) supplemented with 
0.2% yeast extract (BBL) (THY) (189).  Antibiotics were added to the medium when required at the 
following concentrations: Kanamycin 25 g ml-1 or chloramphenicol 750 g ml-1 for E. coli; 
Kanamycin 500 g ml-1, chloramphenicol 3 g ml-1 or streptomycin 1 mg ml-1 for S. iniae.  Bacteria 
were routinely cultured overnight, diluted 1:50 in fresh medium, and grown to mid-exponential phase 
(OD600 = 0.225) unless otherwise stated.  Bacterial growth curves were performed in 96-well plates as 
described in Chapter 2. 
Construction of S. iniae overexpression mutants.  The primers 5’murA.PstI 
(AAAACTGCAGGAGAAGAAGAATAAAGCCTATAGTG) and 3’ murA.ApaI (TTGGGCCCCTAA 
AGGCCTTTATTTGTCTTTG) were used to amplify an 860 base pair (bp) fragment containing the 
MurNAc-L-alanine amidase (murA) (sin.1445).  The fragment was inserted into the PstI/ApaI sites of 
the vector pLZ12-km (116) generating pLZ12-km-murA.  The promoter of the hyaluronic acid 
synthesis operon in Streptococcus pyogenes (67) was PCR amplified using primers 5’ hasApro.BglII 
(GGAAGATCTCAGATGAAGTTGTACTCCCTG) and 3’hasApro.BamH1 (CGCGGATCCGGCAC 
AATTACACCTCTTC).  This fragment was inserted into the BglI/BamH1 sites in pLZ12-km-murA to 
generate the final construct pLZ12-hasApro.murA. 
The vector pLZ12-km-hasApro.murA was cut with PstI and ApaI to remove murA generating 
pLZ12-km-hasApro. The primers 5’oatA.PstI (TGCACTGCAGCTTTAAACAGGGGATTTATCAAA 
AATG) and 3’oatA.ApaI (TGGGGGCCCGACCTTATTTGGCCTTATTTTTG) were used to PCR 
amplify an 1815 bp fragment containing the peptidoglycan O-acetyltransferase (oatA) (Sin.29).  This 
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fragment was inserted into the PstI/ApaI sites of pLZ12-km-hasApro to generate the final construct 
pLZ12-km-hasApro.oatA.  Both pLZ12-km-hasApro.murA and pLZ12-km-hasApro.oatA were 
transformed into S. iniae as previously described (201). 
Whole blood and neutrophil infection assays.  Primary neutrophils were isolated from human 
whole blood, and infections were performed in either whole blood or neutrophil preparations as 
described in Chapter 2.  For competition assays, neutrophils were infected as before with minor 
variations.  Mid-exponential phase cultures were adjusted to 1 x 105 CFU ml-1 in PBS, from which 
equal volumes were pooled and inoculated 1:50 (20 l volume) into 1 ml neutrophil preparations.  
Samples were incubated at 37 oC for 3 hr with gentle rotation, followed by serial dilution and replica 
plating on THY agar  1000 g ml-1 streptomycin for bacterial enumeration.  The competitive index 
(CI) was calculated by dividing the output ratio (mutant/wild type) by the input ratio (mutant/wild 
type).   
Confocal laser scanning fluorescence microscopy.  S. iniae neutrophil infections were 
performed as above for 1 hr.  One hundred microliters of the sample was loaded into a cytology funnel 
(Thermo), centrifuged onto glass slides for 3 min at 700 rpm in a Cytospin 1 centrifuge (Shandon 
Elliott) and fixed in 4% paraformaldehyde (Sigma) for 15 min at room temperature.  Fixed cells were 
washed 3 times in PBS and treated for 30 min with 100 l of permeabilization buffer (0.2% Tween 20 
in PBS + 10% mutanolysin).  Cells were washed in PBS and covered for 30 min in blocking buffer 
(2% cold water fish gelatin (Sigma) in PBS).  One hundred microliters of a polyclonal anti-S. iniae 
antibody was added to the cells for 2 hr, followed by washing 3 times in PBS.  One hundred 
microliters of a secondary Alexa Fluor® 488-conjugated goat anti-rabbit antibody (Molecular Probes) 
was added to the cells for 30 min, and again washed 3 times with PBS.  This procedure was repeated a 
second time using a monoclonal antibody specific for human PMN secondary granule marker CD107A 
(LAMP1) (Santa Cruz Biotechnology) and a secondary Alexa Fluor® TRITC-conjugated goat anti-
   
      67
mouse antibody (Molecular Probes), or using a primary goat antibody for staining of human PMN 
azurophil (primary) granule marker CD63 (Santa Cruz Biotechnology) and a secondary rhodamine-
conjugated chicken anti-goat antibody (Santa Cruz Biotechnology).  Prepared cells were mounted in 
ProLong® Gold antifade reagent with DAPI (Molecular Probes).  Co-localization was determined by 
fluorescent microscopy using a Leica TCS SP5 Laser Scanning Confocal Microscope.  
Antimicrobial sensitivity assays.  Working concentrations of the following antimicrobials 
were prepared in THY broth: colistin (500 g ml-1; Sigma), gramicidin (1.5 g ml-1; Sigma), 
carbenicillin (6 g ml-1; Sigma), methicillin (16 g ml-1; Sigma), teicoplanin (0.07 g ml-1; Sigma), 
bacitracin (5 g ml-1; Sigma), nisin (40 g ml-1; Sigma) and LL-37 (500 g ml-1; Anaspec).  Three 
hundred microliter stock solutions were added to the last column of a 96-well flat bottom plate, and 
serially diluted 1:2 into 150 l of THY broth.  For lysozyme treatments, wells were prepared with 
increasing concentrations of chicken egg white lysozyme (Sigma, 40K units mg-1) from 2.5 mg ml-1 to 
25 mg ml-1 in 150 l total volume THY broth.  Mid-exponential phase bacterial cultures were washed 
twice in PBS and normalized to 1 x 105 CFU ml-1.  Ten microliters of this resuspension was added to 
each well, and plates were incubated overnight at 37oC.  OD600 readings were measured using a 
VersaMax microplate reader (Molecular Diagnostics).  The minimal inhibitory concentration (MIC) 
was scored as the lowest antimicrobial concentration with no detectable growth.  For assays using LL-
37 antimicrobial assays were performed as described above except PBS was used in place of THY 
broth.  Plates were incubated at 37oC for only 3 hr, followed by serial dilution and plating on THY 
agar.  Minimal bactericidal concentration (MBC) was scored as the lowest antimicrobial concentration 
with no detectable growth. 
Bacterial surface charge assay.  Bacteria grown in THY medium were normalized to an 
OD600 = 6.0.  Cultures were washed 2 times in 20 mM morpholinepropane-sulfonic acid (MOPS) 
buffer (pH 7.0) and resuspended in 1 ml of the same buffer.  Ten microliters of 50 mg ml-1 cytochrome 
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c (Sigma) was added, mixed well and incubated 15 min at room temperature.  Samples were 
centrifuged 13,000 x g for 5 min, supernatants were collected and measured at OD530 to determine the 
amount of cytochrome c remaining.  Tubes containing no bacteria were used as an input control.  The 
percentage cytochrome c bound was calculated with the following formula:  [1- (output OD530/input 
OD530)] x 100.   
RNA isolation and quantitative PCR.  Ten milliliters of bacterial cultures were used to purify 
total RNA as described in chapter 2.  For synthesis of cDNA, 2 g of total RNA was combined in 20 
l reaction volumes with 0.2 M reverse primer mix (4 M mixture of each of the reverse primers 
listed below), 0.5 mM dNTP mix, 1X RT buffer, and 200 U of Maxima® Reverse Transcriptase 
(Fermentas).  Reactions were incubated at 60 oC for 30 min followed by 85 oC for 5 min.  For qPCR 
reactions, 1 l of cDNA was combined in 20 l total reaction volumes with 0.2 M forward and 
reverse primers, and 1X Maxima® SYBR Green master mix (Fermentas) per manufacturer instructions.  
Primer sequences are as follows: recA (sin.996) fwd 5’-CTCAGGTGCTGTTGATTTGG-3’, rev 5’-
TGCAGAGAGTTTACGCATGG-3’; murA (sin.1445) fwd 5’-CGTAGTCGTGTATTT-3’, rev 5’-
TTGGGTTGTATGGTGAAGCA-3’; oatA (sin.29) fwd 5’-CTTTTCGGCTTTGTTCTTGC-3’, rev 5’-
TCCGCAAAGTATGTCAGCAC-3’; dltA (sin.295) fwd 5’-CACCGGTATGGTAAGCAGGT-3’, rev 
5’-AAACGGAGAGCAAGGTGAAA-3’; pgdA (sin.822) fwd 5’-GATGGTCCAAACCCTGTGAC-3’, 
rev 5’-ACCCGCTTCCTTGACTTTTT-3’; tagO (sin.1228) fwd 5’-GGTTCCTATGCCAAGTGGTG-
3’, rev 5’-ATTGCCGCTCCAATAACAAC-3’.  Reactions were performed in triplicate using a BioRad 
iCycler with the following cycling conditions: 10 min at 95 oC, 40 cycles of 15 sec 95 oC and 1 min 60 
oC.  Melting curves were performed after completion of each experiment.  Relative fold change in gene 
expression was calculated by 2-(CT) as described in chapter 2. 
Isolation and purification of peptidoglycan.  S. iniae strains subcultured in 1 L of THY at 37 
oC to early stationary phase were rapidly cooled on ice for 5 min, and harvested by centrifugation 
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(9,000 x g, 4oC) for 10 min.  The pellet was resuspended in 15 ml of cold water and transferred 
dropwise into 50 ml of boiling 4% sodium dodecyl sulfate (SDS) (Sigma) for 30 min.  The SDS 
insoluble fraction was collected by centrifugation (9,000 x g, 25oC) for 10 min, and washed with 60 oC 
water until the SDS was undetectable by methylene blue assay (120).  The cell wall fraction was 
resuspended in 1 ml of 100 mM Tris-HCl (pH 7.5), 20 mM MgSO4 containing 10 g ml-1 DNaseI 
(Qiagen), 250 g ml-1 RNaseA (Qiagen) and incubated for 2 hr at 37 oC.  Calcium chloride was 
adjusted to a final concentration of 10 mM, and 100 g Trypsin was added to the mixture prior to 
incubation overnight at 37 oC.  The samples were boiled in 1% SDS for 5 min to denature trypsin, and 
the samples were washed clean of SDS as before.  The purified peptidoglycan was lyophilized and 
stored for later analysis. 
Analysis of muropepetide composition. Muropeptides were analyzed as previously described 
with minor variations (174).  Five milligrams of lyophilized cell wall preparations were resuspended in 
500 l 0.1M Tris HCl (pH 7) and 20 l of mutanolysin (5K U ml-1; Sigma), and incubated at 37oC 
overnight.  Samples were boiled 5 min, and the insoluble fraction was separated by centrifugation at 
13,000 x g for 2 min.  The muropeptide-containing supernatants were lyophilized, and resuspended in 
5 l of a 0.2 M disodium 8-amino-1,3,6-naphthalenetrisulfonate (ANTS; Invitrogen) solution in 15% 
Acetic Acid (Fisher) and 5 l of  a 1 M sodium cyanoborohydride (Acros) solution in DMSO.  The 
samples were incubated overnight at 37 oC, dried by centrifugal vacuum and resuspended in 200 l 
loading buffer (62.5 mM Tris HCl pH 6.8, 20% glycerol).  One micromole of carbohydrate standards 
of glucose (Sigma), maltose (Fisher), maltotriose (Acros), maltotetraose (MP Biomedicals), 
maltopentaose (Sigma) and maltohexaose (MP Biomedicals) were also ANTS-labeled and resuspended 
in 1 ml loading buffer.  Labeled standards were combined to a final mixture of 1 nmol l-1 each. 
Fluorophore-assisted carbohydrate electrophoresis (FACE) was performed in a Hoefer S600 gel 
apparatus.  The 0.5 mm-thick acrylamide gels (18 cm x 16 cm) were composed of a stacking (8% 
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acrylamide, 0.2% bisacrylamide, 0.3 M Tris buffer pH 8.9) and running (32% polyacrylamide, 2.4% 
bisacrylamide, 0.3 M Tris buffer pH 8.9) gel component.  Fifteen microliters of prepared samples were 
separated by electrophoresis at 4 oC for 2.5 hr, 35 mA in running buffer (0.192 M glycine, 25 mM Tris 
pH 8.9).  The muropeptide bands were visualized by UV exposure (310 nM) and photographed using 
Cannon Powershot A650IS camera.  Gels were analyzed for relative band intensity using Gel-Pro® 
Analyzer software (MediaCybernetics). 
 Determination of peptidoglycan acetylation. For quantification of peptidoglycan acetylation 
30 mg of lyophilized cell wall preparations were resuspended in 1.5 ml  80 mM sodium hydroxide, and 
incubated at 37oC for 3 hr with shaking.  The samples were ultracentrifuged (100,000 x g, 25oC) for 30 
min to separate the insoluble wall fraction.  The amount of released sodium acetate in the supernatant 
was assayed with the acetic acid (AK) kit (Megazyme) using a VersaMax microplate reader 
(Molecular Diagnostics).  Standard curves were prepared from serial dilutions of sodium acetate 
(Sigma) for quantification. 
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Results 
CpsY does not influence neutrophil phagosomal maturation.  Because CpsY is critical for 
intracellular survival in neutrophils, we sought to determine the mechanism behind this protective 
function.  S. pyogenes has been shown to escape neutrophil phagocytic killing by inhibiting fusion of 
azurophilic granules with the maturing phagosome (269).  To test whether CpsY functions to disrupt 
neutrophil phagosomal maturation in a similar manner, infected neutrophils were fixed and dual 
immunostained with antibodies against S. iniae, and either the secondary granule marker CD107A or 
azurophilic granule marker CD63.  Laser confocal fluorescent microscopy images revealed that both 
WT and the cpsY mutant colocalize with secondary (Fig. 19A) and azurophilic granule markers (Fig. 
19B), implying containment within a mature phagosome.  The data suggest that S. iniae does not 
manipulate phagosomal maturation in neutrophils as observed for S. pyogenes.  This also indicates that 
the protective function imparted by CpsY must occur within a mature neutrophil phagosome. 
Though phagosomal maturation appears unaltered, CpsY may serve a protective role by 
regulating factors that in some way disrupt the microenvironment within a mature phagosome.  To 
address this possible scenario, a 1:1 co-infection of neutrophils with WT S. iniae and the cpsY mutant 
was performed to determine if the CpsY protein produced in the WT strain could rescue the mutant 
strain when inhabiting the same phagosome.  Co-infection of neutrophils had no effect on the cpsY 
mutant, resulting in significant killing compared to WT (p < 0.01) and an extremely low competitive 
index of 0.06 (Fig 20).  Furthermore, when neutrophil phagocytosis was inhibited by pretreatment with 
cytochalasin D (CD) or heat-inactivation of serum (HIS), growth of the cpsY mutant was restored to 
the levels observed in serum alone (Fig 20).  Therefore, these results indicate that CpsY does not 
function to manipulate phagosomal maturation of neutrophils, but rather must regulate factors that 
provide direct protection to S. iniae from neutrophil killing mechanisms within a mature phagosome.   
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Figure 19.  S. iniae colocalization with neutrophil granule markers CD107A and CD63.  Infected 
Neutrophils were analyzed by confocal laser scanning fluorescence microscopy for localization of S. 
iniae WT or cpsY (green) in relation to the human neutrophil secondary granule marker CD107A 
(red) (A), or human neutrophil azurophil (primary) granule marker CD63 (red) (B).  Shown is a 
maximum projection of a sequential scan 
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Figure 20. Neutrophil competition assay. Mid-logarithmic cultures of S. iniae WT (grey bars) and 
cpsY (white bars) were inoculated at a 1:1 ratio into 1 ml DMEM with 50% human serum (Ser) or 50 
% heat-inactivated serum (HIS). Human neutrophils (N) were added at a ratio of 1000:1 (N:bacteria).  
If specified, neutrophils were pretreated with 10 g ml-1 cytochalasin D (CD) for 30 min to inhibit 
phagocytosis.  Samples were incubated at 37 oC for 3 hr with gentle rotation, followed by serial 
dilution and replica plating on TP plates  1000 g ml-1 streptomycin for enumeration of bacterial 
CFU.  The competitive index (CI) was determined as described in materials and methods. Error bars 
represent  standard error.  * p < 0.001.  
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  The cpsY mutant has increased lysozyme sensitivity.  Many of the bactericidal compounds 
contained within a mature neutrophil phagosome target components of the bacterial cell wall.  The 
susceptibility of the cpsY mutant to neutrophil-mediated killing could imply that CpsY regulates 
factors involved in cell wall physiology.  This could manifest as a decreased resistance to cell wall-
targeting antibiotics or antimicrobial peptides.  No differences in the minimal inhibitory concentration 
(MIC) were observed for the antibiotics colistin, gramicidin, carbenecillin, methicillin, teicoplanin, 
bacitracin, or the antimicrobial peptides nisin and LL-37 (Table 3).  However, the cpsY mutant was 
significantly more sensitive to lysozyme with a 50% decrease in the MIC compared to WT (Table 3).  
The increased sensitivity of the cpsY mutant specifically to lysozyme suggests possible chemical 
alterations in the cell wall (21).  In support of this, the cpsY mutant displayed an altered surface 
charge compared to the WT strain as determined by cytochrome C binding (Fig. 21).  Taken together, 
the data provide evidence for CpsY in the regulation of factors involved in modification of the cell 
wall. 
Deletion of cpsY reduces peptidoglycan acetylation.  Lysozyme is an important component 
of epithelial secretions and phagocytic cells (34, 63, 66), and thus an obstacle necessary for pathogenic 
species to overcome.  Lysozyme cleaves the -(1,4)-glycosidic bonds between the N-acetylmuramyl 
(MurNAc) and N-acetylglucosamyl (GlcNAc) residues of peptidoglycan (PG).  Chemical 
modifications of PG that increase lysozyme resistance include both the addition of O-linked acetyl 
groups to the MurNAc residues by the OatA acetyltransferase (20), or removal of N-linked acetyl 
groups of the GlcNAc residues by the PgdA deacetylase (299).  Furthermore, the addition of wall 
teichoic acids and their D-alanylation have been shown to affect susceptibility to many of the 
antimicrobial peptides contained within neutrophil granules (235).  To determine if CpsY influences 
the expression of genes involved in these processes, we performed quantitative PCR (qPCR) on both 
mid-logarithmic and stationary phase cultures of WT S. iniae and the cpsY mutant.   Expression of a 
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Figure 21.  Measurement of bacterial cell surface charge.  S. iniae WT or cpsY were normalized to an 
OD600 = 6.0, washed twice and resuspended in 20 mM MOPS buffer with 0.5 mg ml-1 cytochrome c 
for 5 min.  Samples were centrifuged and the OD540 of the supernatant was measured. The data 
represent percentage bound compared to input control.  Error bars represent  standard error.   * p < 
0.01 
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putative PG O-acetyltransferase (oatA) was decreased > 2-fold in the cpsY mutant relative to WT 
(Table 4).  No change in expression was observed for genes involved in teichoic acid biosynthesis 
(tagO), D-alanylation of teichoic acids (dltA) or PG N-deacetylation (pgdA). 
To determine whether the decreased expression of oatA in the cpsY mutant was accompanied 
with an actual decrease in PG acetylation, purified PG preparations were treated briefly with 80 mM 
NaOH to release all O-linked acetyl groups (21).  Quantification of released acetyl groups revealed > 
20% decrease in the acetylation of PG from the cpsY mutant (Table 5).  Thus the increased 
susceptibility of the cpsY mutant to lysozyme and intracellular killing by neutrophils may be due to 
an inability to properly acetylate the cell wall. 
The cpsY mutant contains altered muropeptide profiles.  The CpsY ortholog MtaR of S. 
agalactiae was previously shown to affect the expression of a diverse gene set (42).  In an attempt to 
gain further insight into the S. iniae CpsY regulon, the microarray data obtained from that study was 
examined for differential expression of genes with probable effects on cell wall physiology.  Relative 
expression of a gene encoding a putative N-acetylmuramoyl-L-alanine amidase (SAN_0845) was 
found to be increased over 2-fold compared to WT.  Analysis of the S. iniae ortholog (murA) by qPCR 
revealed the same 2-fold increased expression for the cpsY mutant relative to WT (Table 4).  A 
mutant strain was accordingly designed to mimic the cpsY mutant by expressing MurA under the 
transcriptional control of a strong promoter within a WT background (10A63) in order to investigate 
whether overexpression of MurA was responsible for the observed phenotypes associated with the 
cpsY mutant. 
N-acetylmuramoyl-L-alanine amidases (EC 3.5.1.28) breakdown PG muropeptides (single 
disaccharide of GlcNAc and MurNAc with a peptide component) by hydrolyzing the bond between the 
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Table 4.  S. iniae qPCR results  
Gene Function Pathway Phasea FCNb 
murA MurNAc-L-alanine amidase Peptidoglycan recycling ML 2.41  0.13 
   ST 2.04  0.01 
oatA Putative O-acetyltransferase Peptidoglycan acetylation ML 0.43  0.07 
   ST 0.39  0.05 
dltA D-alanine-poly(phosphoribitol) ligase Teichoic Acid D-alanylization ML 1.09  0.12 
   ST 1.09  0.12 
pgdA Peptidoglycan GlcNAc deacetylase Peptidoglycan deacetylation ML 1.09  0.15 
   ST 1.37  0.70 
tagO UDP-GlcNAc 1-P transferase Teichoic Acid biosynthesis ML 1.17  0.18 
   ST 0.95  0.09 
aGrowth phase: mid-logarithmic (ML); stationary (ST). 
bRelative fold change (N) gene expression for cpsY compared to WT  (CT method). 
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Table 5. Peptidoglycan acetylation 
Strain NaOAc concentration (pmol mg-1) a
WT 300.58  23.08 
cpsY 238.32  10.16 
a pmol of released sodium acetate per mg of 
purified peptidoglycan  
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muramoyl residue of the glycan backbone and the L-amino acid residue of the peptide side chain, a 
process required for cell division and PG recycling (245).  An overproduction of these amidases could 
result in disruption of the muropeptide unit, resulting in an unstable cell wall and an increased 
susceptibility to neutrophil bactericidal killing mechanisms.  To determine if overexpression of murA 
altered the muropeptide composition of the cpsY mutant, muropeptides were prepared by mutanolysin 
treatment of purified PG from WT S. iniae, the cpsY mutant and strain 10A63.  These samples were 
then analyzed by fluorophore-assisted carbohydrate electrophoresis (FACE) (314), which allows for 
the differentiation of muropeptides based on their electrophoretic mobility profile.  FACE analysis 
revealed that the relative concentration of soluble oligomeric muropeptide structures (crosslinked 
muropeptides) in the cpsY mutant was approximately half that of the WT strain (Table 6; M1-M5).  
This was accompanied by an increase in monomeric muropeptides (individual disaccharides of 
GlcNAc and MurNAc  peptides) (Table 6; M6-M7) and free MurNAc (M9) for the cpsY mutant.  
The 10A63 strain displayed some similarities to that of the cpsY mutant; however, the other 
differences were observed which differed from WT and the cpsY mutant.  These results demonstrate 
that the overexpression of murA observed in the cpsY mutant may significantly alter the PG 
muropeptide profile; however, this is likely an additive effect in combination with other processes (i.e. 
decreased acetylation) because overexpression of murA alone (10A63) is not enough to mimic the 
muropeptide profile of the cpsY mutant.  This alteration in the cpsY mutant could suggest a 
weakness in the stability of the cell wall, which could increase susceptibility of the cpsY mutant to 
neutrophil killing mechanisms. 
Individual complementation of the cpsY mutant does not rescue growth in vitro.  
Deletion of cpsY was previously shown to affect S. iniae growth patterns such that the cpsY mutant 
cultured in THY medium displayed a significant decrease in cell density upon entry into stationary 
phase (Fig. 5).  In contrast, supplementing THY medium with 2% proteose peptone allowed the cpsY  
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Table 6. Muropeptide percent compositiona  
Muropeptide Compoundb WT cpsY 10A63 
M1 Multimeric MurNAc-peptides 6.61    1.28 3.22    0.99 4.37    1.05 
M2  3.29    0.42 2.53    1.11 3.14    0.54 
M3  3.94    0.37 1.64    0.69 3.94    0.81 
M4  15.47  3.62 6.97    2.75 12.99  1.51 
M5  7.47    0.98 3.92    1.35 6.52    1.26 
M6  5.76    2.78 7.15    5.98 0.30    0.12 
M7 MurNAc-peptide 39.71  1.24 47.66  3.17 47.70  1.98 
M8 GlcNAc 2.47    0.68 2.31    1.27 5.11    1.29 
M9 MurNAc 15.29  3.19 24.59 2.61 15.92  1.75 
a Determined by FACE analysis  
b Muropeptide compound based on electrophoresis profile relative to known carbohydrate 
standards (314). 
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mutant to reach a final cell density significantly greater than WT (Fig. 5).  As shown here, 
complementation of the cpsY mutant by expressing CpsY in trans (6A19) had a negligible effect on 
growth (Fig. 22).  The inability for CpsY complementation suggests that normal CpsY-dependent 
regulation of effectors involved in growth is tightly controlled. 
To determine whether a deficiency in OatA expression was the causative factor for aberrant 
growth of the cpsY mutant, strains were designed to circumvent the normal CpsY-dependent 
regulation by expressing OatA under transcriptional control of a strong promoter in the cpsY mutant 
(11A26) as well as a WT control (11A25).  S. iniae WT, the cpsY mutant, and strains 11A25, 11A26 
and 10A63 were then cultured in THY or THY supplemented with 2% proteose peptone (TP) and 
growth was monitored by measuring OD600 every 30 min.  Overexpressing OatA (11A26) did not 
rescue growth of the cpsY strain (Fig. 22).  Rather, both 11A25 and 11A26 appeared to delay the start 
of exponential growth, and showed a significant decrease in cell density by stationary phase relative to 
their parent background (Fig. 22).  Over expression of the murA gene in 10A63 resulted in no 
deviation from WT growth (Fig. 22).  The data suggest that the aberrant growth of the cpsY mutant is 
a complex phenotype, which cannot be rescued or mimicked by individual complementation of CpsY-
regulated genes. 
Complementation of the cpsY mutant does not prevent killing in whole blood.  We sought 
to determine whether the altered expression of OatA or MurA in the cpsY mutant was directly 
responsible for the susceptibility to neutrophil-mediated killing in whole blood.  S. iniae WT, the 
cpsY mutant, and strains 6A19, 10A63, 11A25 and 11A26 were incubated in whole blood for 3 hr at 
37 oC and plated to determine bacterial survival.  S. iniae WT and strains 11A25 and 10A63 
constructed in a WT background were able survive in whole blood, whereas the cpsY mutant and 
strains 6A19 and 11A26 constructed in a cpsY background were completely killed (Fig. 23).  
Pretreatment with CD rescued growth for all strains indicating that the observed attenuation was due to 
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Figure 22. Bacterial growth curves.  Overnight cultures were diluted 1:50 into 96-well plates 
containing 200 l of THY (A) or TP (B).  Plates were incubated at 37 oC in 5% CO2, and OD600 
measurements were recorded over 6.5 hr.  Error bars represent  standard error.   *p < 0.05 for all 
cpsY background strains (cpsY, 11A26, 6A19) compared to WT. 
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Figure 23.  S. iniae survival in human whole blood.  Mid-logarithmic phase cultures were diluted into 
1 ml heparinized human whole blood, and incubated at 37 oC with gentle rotation.  Samples were 
serially diluted and plated on THY for enumeration of bacterial CFU.  For certain conditions blood 
was pretreated for 30 min with 10 g ml-1 CD to inhibit neutrophil phagocytosis.  Error bars represent 
 standard error.   *p < 0.05.  
 
   
      85
phagocytosis by neutrophils as previously described.  To note, growth of 11A25 and 11A26 was 
significantly less than the respective parent strains (p < 0.01), which correlates with the same growth 
restriction for both strains observed in THY medium (Fig. 22).  Overall the data indicate that the 
protective effect of CpsY from neutrophil-mediated killing is through the tight regulation of multiple 
factors.  
Analysis of CpsY-regulated promoters.  Previous work has shown that certain genes under 
transcriptional control by Streptococcal orthologs of CpsY contain a highly conserved regulatory 
element termed Met box within their promoter region (158, 268).  The presence of a Met box in the 
promoter region of a CpsY-regulated methionine ABC transport system (AtmBDE) suggests that this 
same element facilitates CpsY-dependent regulation in S. iniae as well (Fig. 7).  We sought to 
determine if transcriptional regulation of oatA or murA by CpsY could be through this conserved 
element.  The gene encoding OatA is predicted to be the 3rd gene of an operon (Fig 24A).  Whether 
murA is part of an operon in unknown, but the predicted promoter is immediately upstream of murA 
(Fig. 24A).  Analysis of the predicted promoter regions revealed the presence of a Met box within the 
murA promoter, but not the oatA operon promoter (Fig. 24B).  Additionally, although the promoters of 
both murA and atmB contain the canonical Met box, a major structural difference exists for those 
regions.  Twenty-two nucleotides separate the Met box and -35 site in the atmB promoter, whereas 
those elements are separated by 96 nucleotides in the murA promoter (Fig. 24B).  This difference may 
explain why CpsY transcriptionally activates expression of atmB (Table 2) while repressing murA 
(Table 4).  The absence of a Met box for oatA suggests the effect of CpsY on the expression of oatA 
may be indirect or occur in combination with additional factors. 
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Figure 24.  Promoter alignment for CpsY-regulated genes. (A) Genetic locations of AtmBDE 
(Sin.1702-1699), MurA (Sin.1445) and OatA (Sin.29).  (B) Predicted promote sequences obtained 
from GenBank were aligned and plotted using ClustalX.  The predicted -10 and -35 sites are 
underlined, translational start codon is italicized, and predicted Met boxes are shaded. 
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Discussion 
Neutrophil phagocytosis of an opsonized pathogen is an intricate process whereby sequential 
maturation of the phagosome generates a highly bactericidal microenvironment (172, 256).   Pathogens 
within the nascent phagosome are exposed to a burst of reactive oxygen species upon assembly of the 
NADPH oxidase.  Phagosomal maturation ensues with successive fusion of pre-formed gelatinase, 
specific, and azurophilic granules that contain an arsenal of bactericidal compounds (256).  
Engulfed microbes endure a multi-targeted attack within a mature phagosome.  Transporters 
such as the natural resistance-associated macrophage protein 1 (Nramp1) (135) and chelating agents 
like neutrophil gelatinase-associated lipocalin (NGAL) (154) and lactoferrin (217) deprive 
microorganisms of vital metals such as iron, manganese, and zinc.  Bacterial lipid membranes are the 
target of cytotoxic pore-forming antimicrobial peptides such as cathelicidins (241) and defensins (104) 
with bactericidal activity against both Gram negative and Gram positive bacteria.  Furthermore, 
myloperoxidase can react with hydrogen peroxide to generate hypochlorous acid (HOCl), tyrosine 
radicals and reactive nitrogen intermediates, all of which can attack the surface membranes of 
microorganisms (155).  Engulfed pathogens are also exposed to serprocidins (serine proteases with 
microbicidal activity) like proteinase-3, cathepsin G and elastase (48, 250, 264), as well as lysozyme, 
which has both muramidase-dependent and independent antimicrobial activity (211).  
Bacterial pathogens employ 3 characterized strategies for intracellular survival in neutrophils: 
inhibition of phagosomal maturation, survival within a mature phagosome, or escape into the 
cytoplasm (289).  S. pyogenes evades intracellular neutrophil killing by inhibiting phagosomal 
maturation through an uncharacterized mechanism involving M protein (269).  In contrast, we 
demonstrate that phagosomal maturation is unaltered in S. iniae-infected neutrophils, as determined by 
co-localization with both azurophilic and specific granules.  Thus the high degree of attenuation 
observed for the cpsY mutant upon phagocytosis must be due to the disregulation of specific factors 
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required for survival within a mature phagosome.  These CpsY-regulated factors must be acting 
directly on the bacteria rather than manipulating the phagosomal microenvironment due to the inability 
of WT S. iniae to rescue the cpsY mutant during co-infection of neutrophils.  
Protection from the bactericidal components encountered within a mature neutrophil 
phagosome begins in part with sensory input from a variety of two-component systems (TCS), 
resulting in the activation of cell stress response and wall modification programs (160, 173, 233, 240, 
279, 294).  These systems can activate enzymes that allow the bacteria to decorate both the cell 
membrane and cell wall with various chemical modifications.  For example, lipid lysinylation of the 
cellular membrane by MprF (92, 162, 225, 283) (251) and D-alanylation of wall teichoic acids by the 
DltABC locus (55, 100, 157, 159, 161, 235) provide protection from cationic antimicrobial peptides.  
Resistance to lysozyme occurs through PG acetylation of MurNAc residues by the OatA O-
acetyltransferase found in Gram positive organisms (20-21, 68, 126, 294) or the PatA/PatB system in 
Gram negative organisms (206).  Additionally the PgdA N-deacetylase mediates lysozyme resistance 
through deacetylation of PG GluNAc residues (32, 199, 298-299, 301).  The significant increase in 
lysozyme sensitivity of the cpsY mutant without a concomitant change in sensitivity to -lactam 
antibiotics or antimicrobial peptides tested suggests possible specific chemical modifications to PG 
such as O-acetylation or N-deacetylation.  The decrease in oatA expression for the cpsY mutant with a 
concomitant reduction in total PG acetylation suggest that susceptibility to neutrophil-mediated killing 
may be due to the inability to properly acetylate the cell wall. 
The OatA O-acetyltransferase was originally identified in pathogenic staphylococci (20-21), 
and homologs have been described for Streptococcus pneumoniae (68), Enterococcus faecalis (121) 
and Lactococcus lactis (294).  OatA is a membrane spanning protein thought to utilize cytoplasmic 
acetyl-CoA as a donor for the translocation of acetate to the C6 hydroxyl group of MurNAc residues in 
the murein sacculus (166).  In L. lactis the CesSR TCS responds to lysozyme-induced cell envelope 
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stress by activation of OatA through the intermediate SpxB regulator (294).  CesSR homologs  have 
also been shown to respond to cell envelope stress for S. pneumoniae (91, 114), S. mutans (279), S. 
aureus (164), B. licheniformis (302) and B. subtilis (139).  S. iniae also contains a CesSR homolog; 
however, its functionality in cell envelope stress response is unknown.  Whether the reduced PG 
acetylation observed for the cpsY mutant is influenced by the CesSR stress response pathway is yet to 
be determined.  The observed reduction in PG acetylation of the cpsY mutant could alternatively 
represent an inability to accumulate actetylated PG through exponential growth into stationary phase 
rather than an effect of stress response (166, 226).  The absence of a Met box in the predicted oatA 
promoter suggests an indirect effect by CpsY.  Attempts to complement the cpsY mutant through 
overexpression of OatA were unsuccessful, resulting in slight growth retardation and continued 
susceptibility to neutrophil-mediated killing in whole blood.  Similar observations have been made for 
PG hyperacetylation in L. lactis (294) and Lactobacillus planeterum (24), suggesting that tight 
regulation of the O-acetyltransferase is necessary for optimal growth. 
The observed decrease in PG acetylation for the cpsY mutant could result in an increased 
sensitivity to the cell’s own autolysins (29, 224).  These PG hydrolases encompass several distinct 
enzymes including the N-acetylmuramidases, N-acetylglucosaminidases, N-acetylmuramyl–L-alanine 
amidases and lytic transglycosylases, all of which perform specific enzymatic functions necessary for 
cell wall growth, turnover and separation during cellular division (245).  The strict spatial and temporal 
control of these enzymes is critical for prevention of unregulated PG hydrolysis (286).  PG O-
acetylation can inhibit certain autolysins such as lytic transglycosylases (29, 224), whereas others such 
as the N-acetylmuramyl-L-alanine amidases are unaffected (28, 226).  As shown here, CpsY acts as a 
transcriptional repressor of a putative N-acetylmuramoyl-L-alanine amidase (MurA), presumably 
through interactions with the conserved Met box in the MurA promoter.  N-acetylmuramoyl-L-alanine 
amidases play an important role in separation during cell division (51, 106, 124, 166, 237), and can be 
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potent autolysins when overexpressed (124-125).  The increased expression of murA along with 
decreased PG acetylation could render the cpsY mutant susceptible to detrimental restructuring of the 
murein sacculus, thereby increasing the sensitivity to many of the bactericidal factors contained within 
a neutrophil phagosome.  FACE analysis revealed a reduction in the proportion of oligomeric 
muropeptide structures (crosslinked soluble muropeptides) for the cpsY mutant with a concomitant 
increase in single muropeptides and free MurNAc and GluNAc residues, indicative of an altered cell 
wall.  Overexpression of MurA alone in WT S. iniae (10A63) did not produce the same muropeptide 
profile observed for the cpsY mutant, and resulted in little difference from WT for growth or 
susceptibility to killing in whole blood.  Thus simply overexpression of MurA, perhaps without an 
accompanying decrease in PG acetylation, does not explain the susceptibility to neutrophil-mediated 
killing observed for the cpsY mutant.  
CpsY is orthologous to the MetR regulator of methionine metabolism and uptake pathways in 
Gram positive and Gram negative bacteria.  MetR was originally characterized for its regulation of 
methionine supply through activation of both the cobalamin-independent methionine synthase 
(MetE)/5,10-methylenetetrahydrofolate reductase (MetF) for conversion of homocysteine to 
methionine, as well as a methionine ABC transport system (AtmBDE) (268).  S. iniae does not possess 
the genes encoding MetE or MetF, but CpsY does function as a transcriptional activator of AtmBDE.  
MetR mutants of S. mutans and S. agalactiae display a growth defect in serum, which can be rescued 
in the presence of exogenous methionine (42, 259, 268).  In contrast, the serum growth defect of the S. 
iniae cpsY mutant was shown to be independent of methionine.  Rather, the cpsY mutant displayed 
aberrant growth patterns in which the final cell density reached levels significantly greater or less than 
WT dependent upon the culture medium.  This suggests that the CpsY regulon may act on processes 
involved in cell growth and division rather than simply methionine uptake and metabolism.  
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Furthermore this likely involves multiple elements as attempts to individually complement CpsY-
regulated genes were unsuccessful in restoring WT growth. 
In E. coli cellular growth and division was recently shown to be strongly influenced by the 
supply of both S-adenosylmethionine (SAM) and an undefined single-carbon (C1) tetrahydrofolate 
(THF) derivative (317).  Zhang et al. observed that a mutant strain of E. coli  lacking all L-serine 
deaminases was unable to control cellular division resulting in long chains of cells with abnormal 
bulging morphologies when cultured in medium containing 0.5% casamino acids (CAA) (317).  
Supplementing the medium with exogenous SAM partially restored the mutant to the natural rod-
shaped morphology of WT E. coli; however, the cells were still unable to properly separate during 
division resulting in extended chains of long narrow cells.  Moreover, overexpression of the glycine 
cleavage operon (GCV), which breaks down glycine for synthesis of 5,10-methyleneTHF, in the serine 
deaminase mutant fully restored WT cell morphology when cultured in the CAA medium. 
A supply of C1-THF derivatives such as 5,10-methyleneTHF is required for the synthesis of 
methionine, which is then converted to SAM by the S-adenosylmethionine synthase (Fig. 1).  Thus 
mutations which disrupt either the supply of methionine or C1-THF derivatives ultimately limit the 
production of SAM.  Normally the both the GlyA serine hydroxymethyltransferase and GCV act to 
increase cytoplasmic pools of 5,10-methyleneTHF through breakdown of serine and glycine 
respectively.  The buildup excess of cytoplasmic glycine caused by growth in a complex amino acid 
mixture such as CAA can result in the inhibition GlyA.  The resultant accumulation of serine can then 
act to inhibit the GCV, which is then unable to breakdown glycine and the inhibition is exacerbated 
(317).  Normally cellular serine deaminases decrease cytoplasmic serine pools to a stable level so as to 
limit this inhibitory cycle; however, in the E. coli serine deaminase mutant this inhibition could not be 
relieved.  Thus the mutant strain became starved for C1-metabolites due to the inability to generate 
THF derivatives through the breakdown of serine and glycine.  The ability of exogenous SAM to limit 
the bulging cell morphology of the serine deaminase mutant indicates a possible role for SAM in cell 
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wall physiology; however, the ability of GCV overexpression to fully restore WT cellular morphology 
suggests that an additional process influenced by C1-THF derivatives is ultimately involved in cell 
division.  Thus proper cell growth and division appears to depend on the metabolic state of the cell, 
and both C1-THF and SAM may be needed for activation of the cell division machinery (317). 
Intriguingly, MetR is also a transcriptional activator of GlyA in E. coli (65).  A MetR-
dependent increase in GlyA production would increase the cytoplasmic pool of C1-THF derivatives.  
Thus MetR functions to increase production of C1-THF derivatives through transcriptional activation 
of GlyA, as well as activation of methionine synthesis and uptake pathways for generation of SAM, 
both of which are required for proper cell division.  Whether SAM and C1-THF derivatives are 
required for cellular division in S. iniae is unknown.  In addition, CpsY-dependent regulation of GlyA 
expression has not been investigated; however, a canonical Met box exists among streptococcal species 
in the predicted promoter region of a gene encoding a 5,10-methylenetetrahydrofolate dehydrogenase 
(FolD) (Fig. 1) (158), suggesting that that CpsY does regulate C1–THF metabolic processes for 
streptococcal species as well.  Whether disruption of these processes accounts for the growth 
phenotypes and virulence attenuation of the cpsY mutant remains to be determined.  
Methylation reactions involving SAM result in the production of intermediates such as S-
adenosylhomocysteine (SAH) and S-ribosylhomocysteine (SRH), which are recycled back to 
homocysteine by the methylthioadenosine nucleosidase (Pfs) and S-ribosylhomocysteinase (LuxS) 
(Fig. 6).  Mutations of LuxS result in the inability to properly recycle SAH and SRH, and the 
concomitant buildup of SAH in a LuxS mutant can inhibit many SAM-dependent methyltransferases 
(257).  Recently it was observed that LuxS mediates protection of S. pneumoniae from autolysis by the 
major LytA autolysin, an N-acetylmuramyl-L-alanine amidase (17), through an unknown mechanism 
(249).  Whether the LytA-dependent autolytic phenotype in the LuxS mutant was the result of a direct 
disregulation of LytA or an SAH-mediated inhibition of cellular methyltransferases was not 
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determined.  This work does however provide evidence for a link between processes involving both 
SAM and autolysis in streptococci.  Because CpsY influences both of these processes through 
activation of methionine supply pathways which ultimately lead to synthesis of SAM, and direct 
repression of an N-acetylmuramyl-L-alanine amidase, the observed growth phenotypes and virulence 
attenuation of the cpsY mutant could be due to the inability to properly regulate autolysis. 
Protection from LytA-dependent autolysis has also been linked to the CiaRH TCS (111, 205).  
Furthermore, the simultaneous mutation of both ciaRH and luxS has an additive autolytic effect in S. 
pneumoniae (249).  Pneumococcal CiaRH directly influences transcription at 15 promoters, 5 of which 
regulate production of small RNAs involved in the control of stationary-phase autolysis (115).  CiaRH 
has also been shown to play a role in S. agalactiae lysozyme resistance and protection from neutrophil-
mediated killing (240).  Whether the CiaRH TCS of S. iniae also functions to protect the cell from 
autolysis has yet to be determined.  Furthermore it is unknown whether CpsY has a regulatory role in 
the expression of CiaRH or vice versa.  Ultimately it appears that the relationship between SAM and 
control of cellular autolysis is extremely complex and multifaceted, but could have considerable 
influence on cell wall physiology and virulence. 
A delicate balance exists in which SAM and C1 derivatives influence both cellular autolysins 
and division machinery.  These processes are tightly controlled, and disregulation has considerable 
implications on growth and virulence.  CpsY could influence this balance by increasing AtmBDE and 
GlyA production for the generation of SAM and C1 derivatives respectively, while at the same time 
repressing the expression of cellular autolysins (i.e. MurA).  The inability to complement the cpsY 
mutation reflects this pleiotropic function.  CpsY is a complex transcriptional regulator, and the high 
degree of conservation is indicative of its critical importance for basic processes of all prokaryotic 
microorganisms.  Variations in the CpsY regulon, however, can manifest as a diversity of species-
specific phenotypes, and likely represent environmental niche adaptations.  Many different metabolic 
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pathways converge on cell division and PG biosynthesis, and mutants in components of these 
pathways often share similar virulence phenotypes.  For example, S. iniae mutants of 
phosphoglucomutase (PgmA) (44) and S. mutans mutants of phosphoglucosamine mutase (GlmM) 
(311) also display similar increases in lysozyme sensitivity, susceptibility to neutrophil-mediated 
killing and virulence attenuation in vivo.  The common attenuation observed upon mutations within 
these converging pathways suggests that combinational therapies targeting these basic processes would 
be a powerful treatment strategy. 
   
      95
CHAPTER 4 
General Conclusions 
 
Invasive streptococcal disease remains a global health concern that has been exacerbated by 
difficulties in vaccine design and emerging unprotected strains.  The use of alternative models to 
investigate invasive streptococcal disease may provide a necessary understanding of the detailed 
mechanisms behind streptococcal infections.  We describe here the use of Streptococcus iniae as a 
model organism to investigate the role of a conserved transcriptional regulator, CpsY, in invasive 
disease.  CpsY is orthologous to the ubiquitous MetR transcriptional regulator found in Gram negative 
and Gram positive bacteria.  A primary function of MetR is to increase transcription of the genes 
endoding the cobalamin-independent (MetE) and cobalamin-dependent (MetH) methionine synthase 
and 5,10-methyleneTHF reductase (MetF) for biosynthesis of methionine from homocysteine.  In 
Gram negative bacteria MetR also increases expression of the GlyA serine hydroxymethyltransferase 
to increase synthesis of 5,10-methyleneTHF (60), the required methyl donor for the conversion of 
homocysteine to methionine by MetE and MetH.  In Gram positive bacteria, MetR regulation of GlyA 
has never been shown, but MetR does have moderate transcriptional control of the genes encoding an 
ABC methionine transport system, AtmBDE (MetQ1NP).  Thus, a general function of MetR is to 
increase cellular methionine pools through transcriptional activation of de-novo biosynthetic and 
transport machinery.  
In Gram negative bacteria, a second level of transcriptional control of methionine synthesis and 
transport processes involves the MetJ:SAM repressor complex.  When SAM levels are high, indicative 
of a sufficient methionine pool, MetJ utilizes SAM as a cofactor to bind to the Gram negative Metbox 
within the promoter regions of most genes involved in the synthesis of methionine as well as glyA 
encoding a serine hydroxymethyltransferase.  When SAM levels drop, indicative of a shrinking 
methionine pool, this repression is relieved, allowing the bacteria to quickly respond to decreasing 
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SAM levels as a trigger to increase methionine biosynthesis before cellular methionine concentrations 
drop to a critical level, which could effect translational processes.   This also includes derepression of 
the genes encoding the methionine transporter (AtmBDE) to import extracellular methionine, although 
multiple transport systems are thought to have methionine transport capability (103, 143).  There are 
no known homologs of MetJ in Gram positive organisms. 
In Streptococcus mutans, mutants of metR display a severe growth defect in a chemically 
defined medium lacking methionine (268).  The growth defect is due to the inability to properly 
express the metEF genes for de-novo synthesis of methionine.  This growth defect can be rescued to 
WT levels with a sufficient supply of exogenous methionine.  In S. mutans, MetR has substantially 
greater transcriptional control over metEF than atmBDE (30-fold vs. 3 fold respectively) under 
methionine limitation, or with sufficient methionine in the presence of excess homocysteine, 
suggesting that a primary function of MetR is to regulate de novo synthesis of methionine rather than 
environmental scavenging.  In Streptococcus agalactiae, mutants of mtaR (metR) also display a 
significant growth defect in chemically defined medium in the absence of methionine, and as with S. 
mutans growth is rescued when the medium is supplemented with methionine (259).  Unlike S. mutans, 
MtaR control of MetEF and AtmBDE expression has not been studied under methionine limitation.  In 
the presence of sufficient methionine, MtaR is a transcriptional activator of atmBDE but not metEF 
(42).  This transcriptional activation of atmBDE in the presence of methionine is opposite to the 
expression profile observed in S. mutans (268) suggestive of altered MtaR regulatory function.  
Though S. agalactiae contains MetEF for synthesis of methionine from homocysteine as well as the 
genes for the recycling of SAM to homocysteine, it lacks genes required for the biosynthesis of 
homocysteine from cysteine.  Thus the altered transcriptional control observed for the genes encoding 
the AtmBDE transporter may be reflective of this difference.  Understanding MtaR regulation in S. 
agalactiae under methionine limitation, especially of MetEF, would be of significant value.   
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A small subset of streptococcal pathogens, including S. iniae and S. pyogenes, lack the genes 
encoding MetEF, but do contain homologs of the AtmBDE transporter.  Kovaleva and Gelfand have 
proposed that for these auxotrophs methionine must be obtained through extracellular scavenging and 
peptide recycling (158).  As with S. mutans and S. agalactiae a significant growth defect was observed 
in either serum or THY medium for the S. iniae cpsY mutant; however, this was unable to be rescued 
with exogenous methionine.  This growth defect was not the result of a significant difference in the 
logarithmic growth rate but rather represented an early entry into stationary phase growth resulting in 
decreased final cell density.  Whereas the cpsY mutant displays a significant methionine-independent 
growth defect in serum or THY medium, growth in C-medium was equivalent to WT ( methionine), 
suggesting that the effect of CpsY in S. iniae is not solely to regulate methionine acquisition.  If this 
were the case one would expect a similar growth defect in C-medium as observed in THY.  Moreover, 
the ability to induce significant growth of the cpsY mutant in excess of WT by supplementing either 
THY or C-medium with 2% proteose peptone suggests that the cpsY mutant is unable to properly 
control logarithmic growth and entry into stationary phase dependent upon environmental conditions. 
CpsY regulation of the genes encoding the AtmBDE methionine transporter was shown to 
occur in the presence but not absence of methionine as observed for S. agalactiae.  Moreover, the 
addition of exogenous homocysteine has no significant effect on this regulation in contrast to S. 
mutans.  Additionally, when grown in THY medium supplemented with proteose peptone, CpsY 
appears to act as a transcriptional repressor of atmBDE.  CpsY orthologs have been shown to regulate 
effector targets through the conserved Metbox.  No observable differences were found in the genetic 
location of a Metbox in the atmBDE promoter, which suggests that the drastic differences in 
transcriptional regulation observed under varying environmental conditions is due to additional 
regulation at that site.  
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Thus, although MetR orthologous mutants of S. mutans and S. agalactiae share a methionine-
dependent growth defect in chemically defined medium, MetR regulation of atmBDE is inhibited in 
the presence of methionine for S. mutans but activated for S. agalactiae and S. iniae.  Moreover, 
though CpsY of S. iniae shares similar transcriptional regulation of atmBDE as S. agalactiae, the 
growth defect of the cpsY mutant cannot be rescued with exogenous methionine.  Because S. iniae is 
purely auxotrophic due to the absence of MetEF, it is likely that there are other mechanisms for 
obtaining methionine as proposed for Gram negative bacteria and suggests that the growth effects 
observed for the cpsY mutant are due to a disregulation of other factors.  Moreover, the data highlight 
major differences in the streptococcal methionine supply pathways, suggesting that greater variability 
in methionine acquisition may exist than previously recognized. 
Disregulation of growth as observed for the cpsY mutant in response to peptone 
supplementation could indicate a function for CpsY in either the RelA-dependent stringent response or 
the RelA-independent stress response pathways, which are responsible for coordinating cellular 
division and entry into stationary phase growth in response to amino acid starvation.  The RelA-
dependent stringent response pathway is a cellular stress response to amino acid starvation that has 
widespread effects on growth and virulence (74).  A decrease in cellular amino acids results in a shift 
in the ratio of uncharged to charged tRNAs.  RelA is associated with ribosomes and is activated by the 
presence of uncharged tRNAs in the ribosomal A site.  Activation of RelA triggers its own synthetase 
activity for synthesis of guanosine 3’,5’-bispyrophosphate (ppGpp).  Levels of ppGpp are also 
controlled by SpoT.  SpoT has both a basal ppGpp hydrolase activity and inducible synthetase activity 
dependent upon cellular starvation of carbon sources, fatty acids, phosphates, iron and energy 
depletion.  Together RelA/SpoT are responsible for any accumulation of ppGpp in the cell.  The 
synthesized ppGpp can bind to the -subunit of RNA polymerase to affect promoter specificity and 
facilitates outcompetition of the RpoS sigma factor with the housekeeping 70.  Activation of the 
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stringent response results in a decrease in rRNA biosynthesis, ribosomal proteins and DNA replication 
with a concomitant increase in RpoS, stress proteins and amino acid biosynthesis machinery all of 
which have major implication on bacterial growth and division and help coordinate entry into 
stationary phase growth. 
 Where RelA-dependent responses allow the cell to shut down energy intensive metabolic 
processes in response to nutrient starvation, RelA-independent systems also respond to nutrient 
limitation to initiate several systems involved in nutrient acquisition (272).  The transcriptional 
regulator CodY binds both branched chain amino acids (BCAA) and GTP as cofactors, and inhibits 
expression of many genes associated with adaptive responses to poor growth conditions including 
stationary phase adaptation, virulence and nutrient stress (266).  CodY normally represses these genes 
during exponential growth, and induces them when the cell encounters nutrient limitation as the 
growth rate diminishes.  As cellular amino acid concentrations diminish, RelA reduces GTP pools by 
synthesizing ppGpp.  The reduction of both GTP and BCAA results in derepression of CodY-regulated 
genes.  CodY-regulated genes derepressed under amino acid starvation include the oligopeptide 
permease (opp), intracellular peptidase (pepB), covRS, virulence associated fas operon, streptolysin S 
operon, luxS and ropB which results in activation of the SpeB extracellular protease.  Many of these 
genes encode virulence factors which result in the destruction of host cells and tissues.  This 
destruction most likely releases various peptides and nucleotides, which are then scavenged and 
recycled by the cell for nutrients.  CodY and RelA don’t regulate each other, and thus appear to 
influence the expression of separate, but complimentary, nutrient stress response programs in response 
to decreasing amino acid supplies (192). 
 The specifics as to how CpsY could function as part of RelA-dependent or independent 
response pathways is unclear.  Kang et al. (145) recently described an additional arm of the RelA-
independent amino acid response pathway involving CvfA, a general RNase that regulates virulence 
gene expression in response to nutrient stress and cellular growth phase.  CvfA couples with the 
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glycolytic enzyme enolase to direct degradation of transcripts associated with various aspects of cell 
transport, metabolism and energy production, and increase the expression of virulence factors such as 
SpeB, SLS and the mitogenic factor, an extracellular DNase.  Previously, comparison of protein 
extracts from S. iniae WT and the cpsY mutant revealed an increase in the level of enolase as 
determined by mass spectrometry analysis (201).  Though it is unknown if CpsY directly regulates 
expression of enolase, the increased enolase levels in the cpsY mutant could have significant effects 
on these types of stress response pathways.  Additionally, the B. subtilis CvfA homolog, YmdA, 
drastically affects transcript stability such that mutants of ymdA display over 2-fold increase in the half 
life of cellular mRNA (64).  Although not specifically measured, noticeably more total RNA was 
routinely isolated from the cpsY mutant compared to WT S. iniae.  This could also indicate an 
influence on a similar pathway involving transcript stability. 
A common theme gaining acceptance in the literature is that mutations which limit the ability 
of streptococci to respond to nutritional stress result in a severe attenuation in vivo (148-149).  The 
association of CpsY and its orthologs with methionine biosynthesis and uptake pathways suggests that 
this may also be true for the cpsY mutant.  Mutation of cpsY had significant effects on S. iniae 
virulence due to an increased susceptibility to neutrophil-mediated killing in whole blood.  This 
attenuation in whole blood may explain the significant decrease in CNS invasion previously described 
for the cpsY mutant (185), because the inability for maintaining a significant level of bacteremia is 
considered an important prerequisite for invasion through the vascular endothelial barriers of the brain 
(43, 84, 240, 318).  The susceptibility of the cpsY mutant to neutrophil-mediated killing likely reflects 
an inability to properly modify the cell wall, which leads to an increased sensitivity to lysozyme and 
other neutrophil microbicidal compounds.  This increased lysozyme sensitivity may be due in part to 
the inability to properly acetylate PG, as indicated by decreased expression of oatA and reduction in 
acetylated PG.  The disruption of PG acetylation must be tightly controlled, however, since 
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overexpression of oatA results in growth retardation.  The specifics as to how CpsY influences these 
properties are still unclear.  The lack of a proper Metbox in the predicted oatA promoter region is 
suggestive of an indirect effect by CpsY, but the possibility of weak interactions at the promoter 
cannot be discounted.   
CpsY also appears to directly limit the expression of a major autolysin.  Limiting expression of 
a cell wall autolysin could promote stability of the cell especially in times of environmental stress such 
as that found within mature neutrophil phagosomes.  Attempts to replicate phenotypes of the cpsY 
mutant through overexpression of the autolysin in WT S. iniae were unsuccessful indicating that any 
detrimental effect of overexpressing the autolysin exists only when coupled with other alterations 
occurring in the cpsY mutant.  CpsY-coordinated actions which limit the expression of cell wall 
recycling machinery (i.e. MurA) and increase the ability to protect against wall degrading 
antimicrobial factors (i.e. OatA) could represent an important piece of a stress response pathway for 
survival in vivo.  The inability to complement the cpsY mutant suggests that the regulation imparted 
by CpsY is multifaceted and represents tightly controlled adaptive changes. 
As discussed in chapter 3, a delicate balance exists in terms of how pathways integrated with 
metabolites such as SAM or C1-THF derivatives influence both cellular autolysins (249) and division 
machinery (317).  However, the ineffectiveness of exogenous methionine in rescuing the cpsY mutant 
suggests that the high degree of attenuation is not due strictly to disruption in the regulation of 
methionine supply pathways contributing to cytoplasmic pools of SAM.  The effect of adding 
exogenous SAM to cultures of the cpsY mutant was never tested and would be of interest; however 
no CpsY-dependent effect on the expression or activity of MetK has ever been observed, and in the 
experiments where exogenous methionine was added it is likely that the methionine would be 
converted to SAM if necessary for the cell.  
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The complexity observed with mutation of CpsY in S. iniae suggests that this transcriptional 
regulator maintains tight control over multiple processes.  This would make CpsY a good mark for 
targeted antimicrobial therapies, for example with small molecule inhibitors.  Furthermore, utilizing S. 
iniae to study the regulatory role of CpsY provides a unique system for understanding the complex 
adaptive responses of invasive pathogens to the various stresses imparted by the host.  Streptococcal 
pathogens appear to be able to coordinate nutritional stress responses by upregulation of virulence 
factors to acquire nutrients from the host, while at the same time limiting their own destruction by 
modifying their cell wall to protect against self autolysins and host antimicrobial defenses.  While 
many of the specific details within these complex and highly integrated stress response pathways 
remain to be elucidated, their high degree of conservation among prokaryotes, and the severe loss of 
pathogenicity upon their disruption would indicate these as good therapeutic targets.  
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ABSTRACT 
PLEIOTROPIC REGULATORY FUNCTION OF THE LysR FAMILY TRANSCRIPTIONAL 
REGULATOR CpsY DURING STREPTOCOCCUS INIAE SYSTEMIC INFECTION 
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Degree: Doctor of Philosophy 
The ability of a pathogen to metabolically adapt to the local environment for optimal 
expression of virulence determinants is a continued area of research.  Orthologs of the Streptococcus 
iniae LysR family regulator CpsY have been shown to regulate methionine biosynthesis and uptake 
pathways, but appear to influence expression of several virulence genes as well.  A S. iniae mutant 
with an in-frame deletion of cpsY (cpsY) is highly attenuated in a zebrafish infection model.  The 
cpsY mutant displays a methionine-independent growth defect in serum, which differs from the 
methionine-dependent defect observed for orthologous mutants of S. mutans and S. agalactiae.  On the 
contrary, the cpsY mutant can grow in excess of WT when supplemented with proteose peptone, 
suggesting an inability to properly regulate growth.  CpsY is critical for protection of S. iniae from 
clearance by neutrophils in whole blood, but is dispensable for intracellular survival in macrophages.  
Susceptibility of the cpsY mutant to killing in whole blood is not due to a growth defect because 
inhibition of neutrophil phagocytosis rescues the mutant to WT levels.  S. iniae does not alter 
neutrophil phagosomal maturation, but instead is able to adapt to the extreme bactericidal environment 
of a mature neutrophil phagosome dependent upon CpsY.  This CpsY-dependent adaptation appears to 
involve stabilization of the cell wall in part through peptidoglycan O-acetylation and repression of 
cellular autolysins.  In addition, CpsY may influence these processes by responding to nutritional 
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stress.  The ability of a pathogen to evade neutrophil phagocytic killing mechanisms is critically 
important for dissemination and establishment of a systemic infection.  Understanding how pathogens 
overcome these innate defenses is important for the development of optimal therapeutic strategies for 
invasive infections.  Furthermore S. iniae proves to be a powerful model to investigate bacterial 
adaptations during systemic streptococcal infection. 
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